ID HLAB_HUMAN Reviewed; 362 AA. AC P01889; A0A2I6Q7B5; B0V0B8; G3GN01; O02862; O02956; O02957; O02960; O19555; AC O19556; O19595; O19615; O19624; O19625; O19627; O19641; O19651; O19675; AC O19692; O19758; O19779; O19783; O46702; O62897; O62901; O62915; O62917; AC O62919; O77933; O77959; O78053; O78138; O78160; O78163; O78172; O78173; AC O78180; O78217; O95730; O98140; P01890; P03989; P10317; P10318; P10319; AC P10320; P18463; P18464; P18465; P19373; P30460; P30461; P30462; P30463; AC P30464; P30465; P30466; P30467; P30468; P30469; P30470; P30471; P30472; AC P30473; P30474; P30475; P30476; P30477; P30478; P30479; P30480; P30481; AC P30482; P30483; P30484; P30485; P30486; P30487; P30488; P30489; P30490; AC P30491; P30492; P30493; P30494; P30495; P30496; P30497; P30498; P30513; AC P30685; P79489; P79490; P79496; P79504; P79523; P79524; P79542; P79555; AC Q04826; Q08136; Q29633; Q29636; Q29638; Q29661; Q29665; Q29678; Q29679; AC Q29681; Q29693; Q29695; Q29697; Q29718; Q29742; Q29749; Q29762; Q29764; AC Q29829; Q29836; Q29842; Q29845; Q29846; Q29847; Q29848; Q29850; Q29851; AC Q29852; Q29854; Q29855; Q29857; Q29858; Q29861; Q29924; Q29925; Q29933; AC Q29935; Q29936; Q29940; Q29953; Q29961; Q29982; Q30173; Q30198; Q31603; AC Q31610; Q31612; Q31613; Q546L8; Q546M4; Q5JP37; Q5QT24; Q5RIP1; Q5SRJ2; AC Q5TK76; Q5TK77; Q860I4; Q861B5; Q8HWF0; Q8MGQ3; Q8MHN4; Q8SNC5; Q95343; AC Q95344; Q95365; Q95369; Q95392; Q95HA3; Q95HA8; Q95HM9; Q95IA6; Q95IB8; AC Q95IH5; Q95J00; Q96IT9; Q9BCM6; Q9BCM7; Q9BCM8; Q9BD06; Q9BD38; Q9BD43; AC Q9GIL3; Q9GIM3; Q9GIX1; Q9GIY5; Q9GIZ0; Q9GIZ9; Q9GJ00; Q9GJ17; Q9GJ20; AC Q9GJ23; Q9GJ31; Q9GJF0; Q9GJM7; Q9MX21; Q9MY37; Q9MY42; Q9MY43; Q9MY61; AC Q9MY75; Q9MY78; Q9MY79; Q9MY84; Q9MY92; Q9MY93; Q9MY94; Q9MYB8; Q9MYC3; AC Q9MYC7; Q9MYF4; Q9MYG1; Q9TP35; Q9TP36; Q9TP37; Q9TP95; Q9TPQ7; Q9TPQ9; AC Q9TPR2; Q9TPR4; Q9TPS6; Q9TPT2; Q9TPT4; Q9TPT6; Q9TPV2; Q9TQG1; Q9TQH3; AC Q9TQH6; Q9TQH7; Q9TQH8; Q9TQH9; Q9TQM2; Q9TQN4; Q9TQN6; Q9UQS8; Q9UQT0; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1991, sequence version 3. DT 27-MAR-2024, entry version 224. DE RecName: Full=HLA class I histocompatibility antigen, B alpha chain; DE AltName: Full=Human leukocyte antigen B; DE Short=HLA-B; DE Flags: Precursor; GN Name=HLA-B {ECO:0000312|HGNC:HGNC:4932}; Synonyms=HLAB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*40:01). RX PubMed=2437025; DOI=10.1007/bf00404425; RA Ways J.W., Lawlor D.A., Wan A.M., Parham P.; RT "A transposable epitope of HLA-B7, B40 molecules."; RL Immunogenetics 25:323-328(1987). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*07:02; B*37:01; B*51:01 AND B*57:01). RX PubMed=2320591; DOI=10.1073/pnas.87.7.2833; RA Ennis P.D., Zemmour J., Salter R.D., Parham P.; RT "Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction: RT frequency and nature of errors produced in amplification."; RL Proc. Natl. Acad. Sci. U.S.A. 87:2833-2837(1990). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*54:01; B*55:01 AND B*56:01). RX PubMed=1737933; RA Hildebrand W.H., Madrigal J.A., Little A.-M., Parham P.; RT "HLA-Bw22: a family of molecules with identity to HLA-B7 in the alpha 1- RT helix."; RL J. Immunol. 148:1155-1162(1992). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*45:01; B*50:01 AND B*78:01). RX PubMed=1431115; RA Madrigal J.A., Belich M.P., Hildebrand W.H., Benjamin R.J., Little A.-M., RA Zemmour J., Ennis P.D., Ward F.E., Petzl-Erler M.L., Martell R.W., RA du Toit E.D., Parham P.; RT "Distinctive HLA-A,B antigens of black populations formed by interallelic RT conversion."; RL J. Immunol. 149:3411-3415(1992). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*49:01). RX PubMed=1385528; RA Hildebrand W.H., Madrigal J.A., Belich M.P., Zemmour J., Ward F.E., RA Williams R.C., Parham P.; RT "Serologic cross-reactivities poorly reflect allelic relationships in the RT HLA-B12 and HLA-B21 groups. Dominant epitopes of the alpha 2 helix."; RL J. Immunol. 149:3563-3568(1992). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*48:01). RX PubMed=1317015; DOI=10.1038/357326a0; RA Belich M.P., Madrigal J.A., Hildebrand W.H., Zemmour J., Williams R.C., RA Luz R., Petzl-Erler M.L., Parham P.; RT "Unusual HLA-B alleles in two tribes of Brazilian Indians."; RL Nature 357:326-329(1992). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*40:02). RX PubMed=1362296; DOI=10.1111/j.1399-0039.1992.tb02053.x; RA Domena J.D., Johnston-Dow L., Parham P.; RT "The B*4002 allele encodes the B61 antigen: B40* is identical to B61."; RL Tissue Antigens 40:254-256(1992). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 13-318 (ALLELE B*40:02). RC TISSUE=Blood; RX PubMed=1481202; DOI=10.1111/j.1399-0039.1992.tb02054.x; RA Lin L., Watanabe Y., Tokunaga K., Kuwata S., Kohsaka T., Akaza T.; RT "A common Japanese haplotype HLA-A26-Cw3-B61-DR9-DQ3 carries HLA-B*4002."; RL Tissue Antigens 40:257-260(1992). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 25-362 (ALLELE B*15:01). RX PubMed=8423049; DOI=10.1007/bf00216833; RA Choo S.Y., Fan L.A., Hansen J.A.; RT "Allelic variations clustered in the antigen binding sites of HLA-Bw62 RT molecules."; RL Immunogenetics 37:108-113(1993). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*59:01). RX PubMed=8362411; DOI=10.1111/j.1399-0039.1993.tb02001.x; RA Hildebrand W.H., Domena J.D., Parham P.; RT "Primary structure shows HLA-B59 to be a hybrid of HLA-B55 and HLA-B51, and RT not a subtype of HLA-B8."; RL Tissue Antigens 41:190-195(1993). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*73:01). RX PubMed=7517915; DOI=10.1007/bf00188185; RA Vilches C., de Pablo R., Herrero M.J., Moreno M.E., Kreisler M.; RT "HLA-B73: an atypical HLA-B molecule carrying a Bw6-epitope motif variant RT and a B pocket identical to HLA-B27."; RL Immunogenetics 40:166-166(1994). RN [12] RP NUCLEOTIDE SEQUENCE [MRNA] OF 25-362 (ALLELE B*15:01). RX PubMed=7521976; DOI=10.1111/j.1399-0039.1994.tb02327.x; RA Hildebrand W.H., Domena J.D., Shen S.Y., Lau M., Terasaki P.I., Bunce M., RA Marsh S.G.E., Guttridge M.G., Bias W.B., Parham P.; RT "HLA-B15: a widespread and diverse family of HLA-B alleles."; RL Tissue Antigens 43:209-218(1994). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*73:01). RX PubMed=7524186; DOI=10.1111/j.1399-0039.1994.tb02344.x; RA Parham P., Arnett K.L., Adams E.J., Barber L.D., Domena J.D., Stewart D., RA Hildebrand W.H., Little A.-M.; RT "The HLA-B73 antigen has a most unusual structure that defines a second RT lineage of HLA-B alleles."; RL Tissue Antigens 43:302-313(1994). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*73:01). RX PubMed=8547229; DOI=10.1111/j.1744-313x.1995.tb00237.x; RA Hoffmann H.J., Kristensen T.J., Jensen T.G., Graugaard B., Lamm L.U.; RT "Antigenic characteristics and cDNA sequences of HLA-B73."; RL Eur. J. Immunogenet. 22:231-240(1995). RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*13:02). RC TISSUE=Blood; RX PubMed=7558929; DOI=10.1016/0198-8859(94)00120-f; RA Lin L., Tokunaga K., Nakajima F., Ishikawa Y., Kashiwase K., Tanaka H., RA Kuwata S., Sideltseva E., Akaza T., Tadokoro K., Shibata Y., RA Chandanayingyong D., Juji T.; RT "Both HLA-B*1301 and B*1302 exist in Asian populations and are associated RT with different haplotypes."; RL Hum. Immunol. 43:51-56(1995). RN [16] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*81:01). RX PubMed=8847228; DOI=10.1016/0198-8859(95)00082-f; RA Ellexson M.E., Zhang G., Stewart D., Lau M., Teresi G., Terasaki P., RA Roe B.A., Hildebrand W.H.; RT "Nucleotide sequence analysis of HLA-B*1523 and B*8101. Dominant alpha- RT helical motifs produce complex serologic recognition patterns for the HLA- RT B''DT'' and HLA-B''NM5'' antigens."; RL Hum. Immunol. 44:103-110(1995). RN [17] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELES B*38:01 AND B*39:02). RX PubMed=7725307; DOI=10.1111/j.1399-0039.1995.tb02410.x; RA Adams E.J., Martinez-Naves E., Arnett K.L., Little A.-M., Tyan D.B., RA Parham P.; RT "HLA-B16 antigens: sequence of the ST-16 antigen, further definition of two RT B38 subtypes and evidence for convergent evolution of B*3902."; RL Tissue Antigens 45:18-26(1995). RN [18] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*81:01). RX PubMed=8851728; DOI=10.1111/j.1399-0039.1996.tb02527.x; RA Vilches C., Sanz L., de Pablo R., Moreno M.E., Puente S., Kreisler M.; RT "Molecular characterization of the new alleles HLA-B*8101 and B*4407."; RL Tissue Antigens 47:139-142(1996). RN [19] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*82:01). RX PubMed=8740766; DOI=10.1111/j.1399-0039.1996.tb02538.x; RA Hurley C.K., Steiner N.K., Hoyer R.J., Menchaca E., Mitton W., Simonis T., RA Hartzman R.J., Johnson A.H., Ng J.; RT "Novel HLA-B alleles, B*8201, B*3515 and B*5106, add to the complexity of RT serologic identification of HLA types."; RL Tissue Antigens 47:179-187(1996). RN [20] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*15:01). RC TISSUE=Blood; RX PubMed=8773315; DOI=10.1111/j.1399-0039.1996.tb02553.x; RA Lin L., Tokunaga K., Tanaka H., Nakajima F., Imanishi T., Kashiwase K., RA Bannai M., Mizuno S., Akaza T., Tadokoro K., Shibata Y., Juji T.; RT "Further molecular diversity in the HLA-B15 group."; RL Tissue Antigens 47:265-274(1996). RN [21] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*58:01). RX PubMed=10395103; DOI=10.1034/j.1399-0039.1999.530603.x; RA Inoue T., Ogawa A., Tokunaga K., Ishikawa Y., Kashiwase K., Tanaka H., RA Park M.H., Jia G.J., Chimge N.-O., Sideltseva E.W., Akaza T., Tadokoro K., RA Takahashi T., Juji T.; RT "Diversity of HLA-B17 alleles and haplotypes in East Asians and a novel Cw6 RT allele (Cw*0604) associated with B*5701."; RL Tissue Antigens 53:534-544(1999). RN [22] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*58:01). RX PubMed=2995352; DOI=10.1016/s0021-9258(17)38967-6; RA Ways J.P., Coppin H.L., Parham P.; RT "The complete primary structure of HLA-Bw58."; RL J. Biol. Chem. 260:11924-11933(1985). RN [23] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES B*27:05). RX PubMed=3011411; DOI=10.1002/j.1460-2075.1986.tb04245.x; RA Seemann G.H.A., Rein R.S., Brown C.S., Ploegh H.L.; RT "Gene conversion-like mechanisms may generate polymorphism in human class I RT genes."; RL EMBO J. 5:547-552(1986). RN [24] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 25-298 (ALLELE B*27:05). RX PubMed=3489755; RA Coppin H.L., McDevitt H.O.; RT "Absence of polymorphism between HLA-B27 genomic exon sequences isolated RT from normal donors and ankylosing spondylitis patients."; RL J. Immunol. 137:2168-2172(1986). RN [25] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*13:02 AND B*47:01). RX PubMed=3257938; DOI=10.1007/bf00376123; RA Zemmour J., Ennis P.D., Parham P., Dupont B.; RT "Comparison of the structure of HLA-Bw47 to HLA-B13 and its relationship to RT 21-hydroxylase deficiency."; RL Immunogenetics 27:281-287(1988). RN [26] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*35:01). RX PubMed=2788131; DOI=10.1007/bf02421534; RA Ooba T., Hayashi H., Karaki S., Tanabe M., Kano K., Takiguchi M.; RT "The structure of HLA-B35 suggests that it is derived from HLA-Bw58 by two RT genetic mechanisms."; RL Immunogenetics 30:76-80(1989). RN [27] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*51:01). RX PubMed=2714852; DOI=10.1007/bf00352839; RA Pohla H., Kuon W., Tabaczewski P., Doerner C., Weiss E.H.; RT "Allelic variation in HLA-B and HLA-C sequences and the evolution of the RT HLA-B alleles."; RL Immunogenetics 29:297-307(1989). RN [28] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES B*08:01; B*13:02; B*14:01; RP B*18:01; B*41:01; B*42:01; B*44:02 AND B*46:01). RX PubMed=2715640; RA Parham P., Lawlor D.A., Lomen C.E., Ennis P.D.; RT "Diversity and diversification of HLA-A,B,C alleles."; RL J. Immunol. 142:3937-3950(1989). RN [29] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*53:01). RX PubMed=1699887; DOI=10.1007/bf02114973; RA Hayashi H., Ooba T., Nakayama S., Sekimata M., Kano K., Takiguchi M.; RT "Allospecificities between HLA-Bw53 and HLA-B35 are generated by RT substitution of the residues associated with HLA-Bw4/Bw6 public epitopes."; RL Immunogenetics 32:195-199(1990). RN [30] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*78:01). RX PubMed=1691230; RA Sekimata M., Hiraiwa M., Andrien M., Dupont E., Karaki S., Yamamoto J., RA Kano K., Takiguchi M.; RT "Allodeterminants and evolution of a novel HLA-B5 CREG antigen, HLA-B RT SNA."; RL J. Immunol. 144:3228-3233(1990). RN [31] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*57:01). RX PubMed=2251138; DOI=10.1093/nar/18.22.6702; RA Isamat M., Girdlestone J., Milstein C.; RT "Nucleotide sequence of an HLA-Bw57 gene."; RL Nucleic Acids Res. 18:6702-6702(1990). RN [32] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*39:02). RX PubMed=8420828; DOI=10.1007/bf00191887; RA Kato N., Karaki S., Kashiwase K., Mueller C., Akaza T., Juji T., Kano K., RA Takiguchi M.; RT "Molecular analysis of HLA-B39 subtypes."; RL Immunogenetics 37:212-216(1993). RN [33] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*40:01), AND NUCLEOTIDE SEQUENCE RP [MRNA] (ALLELE B*67:01). RX PubMed=7517584; DOI=10.1111/j.1399-0039.1994.tb02294.x; RA Little A.-M., Domena J.D., Hildebrand W.H., Shen S.Y., Barber L.D., RA Marsh S.G.E., Bias W.B., Parham P.; RT "HLA-B67: a member of the HLA-B16 family that expresses the ME1 epitope."; RL Tissue Antigens 43:38-43(1994). RN [34] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELES B*07:02; B*08:01; B*18:01; RP B*41:01; B*42:01; B*45:01; B*46:01; B*47:01; B*48:01 AND B*55:01). RC TISSUE=Blood; RX PubMed=12622774; DOI=10.1034/j.1399-0039.2003.610103.x; RA Cox S.T., McWhinnie A.J., Robinson J., Marsh S.G.E., Parham P., RA Madrigal J.A., Little A.-M.; RT "Cloning and sequencing full-length HLA-B and -C genes."; RL Tissue Antigens 61:20-48(2003). RN [35] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*52:01). RX PubMed=21585707; DOI=10.1111/j.1744-313x.2011.01016.x; RA Zhu F., He Y., Zhang W., He J., He J., Xu X., Lv H., Yan L.; RT "Analysis for complete genomic sequence of HLA-B and HLA-C alleles in the RT Chinese Han population."; RL Int. J. Immunogenet. 38:281-284(2011). RN [36] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*73:01). RX PubMed=21868630; DOI=10.1126/science.1209202; RA Abi-Rached L., Jobin M.J., Kulkarni S., McWhinnie A., Dalva K., Gragert L., RA Babrzadeh F., Gharizadeh B., Luo M., Plummer F.A., Kimani J., RA Carrington M., Middleton D., Rajalingam R., Beksac M., Marsh S.G., RA Maiers M., Guethlein L.A., Tavoularis S., Little A.M., Green R.E., RA Norman P.J., Parham P.; RT "The shaping of modern human immune systems by multiregional admixture with RT archaic humans."; RL Science 334:89-94(2011). RN [37] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-322 (ALLELE B*37:01), AND NUCLEOTIDE RP SEQUENCE [MRNA] OF 1-322 (ALLELE B*50:01). RA Hurley C.K., Bei M., Rodriguez S., Johnson A.; RL Submitted (JUN-1994) to the EMBL/GenBank/DDBJ databases. RN [38] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*59:01). RC TISSUE=Blood; RA Lin L., Tokunaga K.; RL Submitted (APR-1995) to the EMBL/GenBank/DDBJ databases. RN [39] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*07:02). RA Ellexson M.E., Zhang L., Hildebrand W.H.; RL Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases. RN [40] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*82:01). RA Ellexson M.E., Hildebrand W.H.; RL Submitted (OCT-1995) to the EMBL/GenBank/DDBJ databases. RN [41] RP NUCLEOTIDE SEQUENCE [MRNA] (ALLELE B*38:01). RA Morlighem G.; RL Submitted (NOV-1995) to the EMBL/GenBank/DDBJ databases. RN [42] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*44:02). RA Dunn P.P.J.; RT "Complete nucleotide sequencing of HLA class I genes."; RL Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases. RN [43] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*07:02). RA Marsh S.G.E.; RT "Intron sequences of HLA class I."; RL Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases. RN [44] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*37:01). RC TISSUE=Blood; RA Cox S.T.; RT "Confirmation of B*3701."; RL Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases. RN [45] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*78:01). RC TISSUE=Blood; RA Cox S.T.; RT "Confirmation of B*7801."; RL Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases. RN [46] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE B*27:01). RA Lazaro A.M., Hou L., Enriquez E., Persaud M., Hurley C.K.; RT "Oncology, C.W.Bill Young DoD Marrow Donor Recruitment and Research RT Program, 11333 Woodglen Dr, Rockville, MD 20852, USA."; RL Submitted (NOV-2017) to the EMBL/GenBank/DDBJ databases. RN [47] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE B*55:01). RC TISSUE=Leukemia; RA Zhou J., Yu W., Tang H., Mei G., Tsang Y.T.M., Bouck J., Gibbs R.A., RA Margolin J.F.; RT "Pediatric leukemia cDNA sequencing project."; RL Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases. RN [48] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE B*08:01). RA Shiina S., Tamiya G., Oka A., Inoko H.; RT "Homo sapiens 2,229,817bp genomic DNA of 6p21.3 HLA class I region."; RL Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases. RN [49] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [50] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE B*07:02). RC TISSUE=Subthalamic nucleus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [51] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [52] RP PROTEIN SEQUENCE OF 25-295 (B*07:02). RX PubMed=518865; DOI=10.1021/bi00592a030; RA Orr H.T., Lopez de Castro J.A., Lancet D., Strominger J.L.; RT "Complete amino acid sequence of a papain-solubilized human RT histocompatibility antigen, HLA-B7. 2. Sequence determination and search RT for homologies."; RL Biochemistry 18:5711-5720(1979). RN [53] RP FUNCTION (ALLELE B*27:05). RX PubMed=1922338; DOI=10.1038/353326a0; RA Jardetzky T.S., Lane W.S., Robinson R.A., Madden D.R., Wiley D.C.; RT "Identification of self peptides bound to purified HLA-B27."; RL Nature 353:326-329(1991). RN [54] RP FUNCTION (ALLELES B*07:02; B*54:01; B*55:01; B*56:01 AND B*67:01). RX PubMed=7743181; DOI=10.1016/s0960-9822(95)00039-x; RA Barber L.D., Gillece-Castro B., Percival L., Li X., Clayberger C., RA Parham P.; RT "Overlap in the repertoires of peptides bound in vivo by a group of related RT class I HLA-B allotypes."; RL Curr. Biol. 5:179-190(1995). RN [55] RP FUNCTION (ALLELE B*27:05). RX PubMed=8879234; DOI=10.1084/jem.184.4.1585; RA Peruzzi M., Wagtmann N., Long E.O.; RT "A p70 killer cell inhibitory receptor specific for several HLA-B allotypes RT discriminates among peptides bound to HLA-B*2705."; RL J. Exp. Med. 184:1585-1590(1996). RN [56] RP INTERACTION WITH B2M, AND INTERACTION WITH CALR AND TAP1-TAP2. RX PubMed=9036970; RA Solheim J.C., Harris M.R., Kindle C.S., Hansen T.H.; RT "Prominence of beta 2-microglobulin, class I heavy chain conformation, and RT tapasin in the interactions of class I heavy chain with calreticulin and RT the transporter associated with antigen processing."; RL J. Immunol. 158:2236-2241(1997). RN [57] RP FUNCTION (ALLELES B*08:01; B*27:05 AND B*44:02), INTERACTION WITH RP TAP1-TAP2, AND SUBCELLULAR LOCATION. RX PubMed=9620674; DOI=10.1016/s1074-7613(00)80558-0; RA Peh C.A., Burrows S.R., Barnden M., Khanna R., Cresswell P., Moss D.J., RA McCluskey J.; RT "HLA-B27-restricted antigen presentation in the absence of tapasin reveals RT polymorphism in mechanisms of HLA class I peptide loading."; RL Immunity 8:531-542(1998). RN [58] RP INTERACTION WITH HTLV-1 ACCESSORY PROTEIN P12I (MICROBIAL INFECTION). RX PubMed=11390610; DOI=10.1128/jvi.75.13.6086-6094.2001; RA Johnson J.M., Nicot C., Fullen J., Ciminale V., Casareto L., Mulloy J.C., RA Jacobson S., Franchini G.; RT "Free major histocompatibility complex class I heavy chain is RT preferentially targeted for degradation by human T-cell RT leukemia/lymphotropic virus type 1 p12(I) protein."; RL J. Virol. 75:6086-6094(2001). RN [59] RP FUNCTION (ALLELE B*18:01). RX PubMed=12366779; DOI=10.1034/j.1399-0039.2002.600103.x; RA Bilsborough J., Panichelli C., Duffour M.T., Warnier G., Lurquin C., RA Schultz E.S., Thielemans K., Corthals J., Boon T., van der Bruggen P.; RT "A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T RT lymphocytes on HLA-B18."; RL Tissue Antigens 60:16-24(2002). RN [60] RP FUNCTION (ALLELE B*18:01). RX PubMed=14978097; DOI=10.4049/jimmunol.172.5.2944; RA Hickman H.D., Luis A.D., Buchli R., Few S.R., Sathiamurthy M., RA VanGundy R.S., Giberson C.F., Hildebrand W.H.; RT "Toward a definition of self: proteomic evaluation of the class I peptide RT repertoire."; RL J. Immunol. 172:2944-2952(2004). RN [61] RP FUNCTION (ALLELE B*27:05). RX PubMed=15113903; DOI=10.1128/jvi.78.10.5216-5222.2004; RA Berkhoff E.G., Boon A.C., Nieuwkoop N.J., Fouchier R.A., Sintnicolaas K., RA Osterhaus A.D., Rimmelzwaan G.F.; RT "A mutation in the HLA-B*2705-restricted NP383-391 epitope affects the RT human influenza A virus-specific cytotoxic T-lymphocyte response in RT vitro."; RL J. Virol. 78:5216-5222(2004). RN [62] RP FUNCTION (ALLELE B*13:02). RX PubMed=17251285; DOI=10.1128/jvi.02689-06; RA Honeyborne I., Prendergast A., Pereyra F., Leslie A., Crawford H., RA Payne R., Reddy S., Bishop K., Moodley E., Nair K., van der Stok M., RA McCarthy N., Rousseau C.M., Addo M., Mullins J.I., Brander C., Kiepiela P., RA Walker B.D., Goulder P.J.; RT "Control of human immunodeficiency virus type 1 is associated with HLA-B*13 RT and targeting of multiple gag-specific CD8+ T-cell epitopes."; RL J. Virol. 81:3667-3672(2007). RN [63] RP FUNCTION (ALLELES B*18:01; B*40:01; B*41:01; B*44:02; B*45:01; B*47:01; RP B*49:01 AND B*50:01). RX PubMed=18991276; DOI=10.1002/eji.200838632; RA Hillen N., Mester G., Lemmel C., Weinzierl A.O., Mueller M., Wernet D., RA Hennenlotter J., Stenzl A., Rammensee H.G., Stevanovic S.; RT "Essential differences in ligand presentation and T cell epitope RT recognition among HLA molecules of the HLA-B44 supertype."; RL Eur. J. Immunol. 38:2993-3003(2008). RN [64] RP FUNCTION (ALLELE B*27:05). RX PubMed=18385228; DOI=10.1128/jvi.02356-07; RA Schneidewind A., Brockman M.A., Sidney J., Wang Y.E., Chen H., RA Suscovich T.J., Li B., Adam R.I., Allgaier R.L., Mothe B.R., Kuntzen T., RA Oniangue-Ndza C., Trocha A., Yu X.G., Brander C., Sette A., Walker B.D., RA Allen T.M.; RT "Structural and functional constraints limit options for cytotoxic T- RT lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human RT immunodeficiency virus type 1 capsid."; RL J. Virol. 82:5594-5605(2008). RN [65] RP FUNCTION (ALLELE B*27:05). RX PubMed=19139562; DOI=10.1172/jci36587; RA Dazert E., Neumann-Haefelin C., Bressanelli S., Fitzmaurice K., Kort J., RA Timm J., McKiernan S., Kelleher D., Gruener N., Tavis J.E., Rosen H.R., RA Shaw J., Bowness P., Blum H.E., Klenerman P., Bartenschlager R., Thimme R.; RT "Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV RT escape from a protective HLA-B27-restricted human immune response."; RL J. Clin. Invest. 119:376-386(2009). RN [66] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [67] RP NOMENCLATURE. RX PubMed=20356336; DOI=10.1111/j.1399-0039.2010.01466.x; RA Marsh S.G., Albert E.D., Bodmer W.F., Bontrop R.E., Dupont B., Erlich H.A., RA Fernandez-Vina M., Geraghty D.E., Holdsworth R., Hurley C.K., Lau M., RA Lee K.W., Mach B., Maiers M., Mayr W.R., Mueller C.R., Parham P., RA Petersdorf E.W., Sasazuki T., Strominger J.L., Svejgaard A., Terasaki P.I., RA Tiercy J.M., Trowsdale J.; RT "Nomenclature for factors of the HLA system, 2010."; RL Tissue Antigens 75:291-455(2010). RN [68] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [69] RP FUNCTION. RX PubMed=23209413; DOI=10.1371/journal.ppat.1003042; RA Schmidt J., Iversen A.K., Tenzer S., Gostick E., Price D.A., Lohmann V., RA Distler U., Bowness P., Schild H., Blum H.E., Klenerman P., RA Neumann-Haefelin C., Thimme R.; RT "Rapid antigen processing and presentation of a protective and RT immunodominant HLA-B*27-restricted hepatitis C virus-specific CD8+ T-cell RT epitope."; RL PLoS Pathog. 8:E1003042-E1003042(2012). RN [70] RP FUNCTION (ALLELE B*18:01). RX PubMed=23749632; DOI=10.4049/jimmunol.1300292; RA Rist M.J., Theodossis A., Croft N.P., Neller M.A., Welland A., Chen Z., RA Sullivan L.C., Burrows J.M., Miles J.J., Brennan R.M., Gras S., Khanna R., RA Brooks A.G., McCluskey J., Purcell A.W., Rossjohn J., Burrows S.R.; RT "HLA peptide length preferences control CD8+ T cell responses."; RL J. Immunol. 191:561-571(2013). RN [71] RP INTERACTION WITH TAPBPL, AND SUBCELLULAR LOCATION. RX PubMed=26439010; DOI=10.7554/elife.09617; RA Hermann C., van Hateren A., Trautwein N., Neerincx A., Duriez P.J., RA Stevanovic S., Trowsdale J., Deane J.E., Elliott T., Boyle L.H.; RT "TAPBPR alters MHC class I peptide presentation by functioning as a peptide RT exchange catalyst."; RL Elife 4:0-0(2015). RN [72] RP FUNCTION (ALLELES B*08:01 AND B*57:01), DOMAIN, BW4 AND BW6 MOTIFS, RP INTERACTION WITH KIR3DL1, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF RP VARIANTS ILE-104 AND ARG-107. RX PubMed=25480565; DOI=10.4049/jimmunol.1402542; RA Saunders P.M., Vivian J.P., Baschuk N., Beddoe T., Widjaja J., RA O'Connor G.M., Hitchen C., Pymm P., Andrews D.M., Gras S., McVicar D.W., RA Rossjohn J., Brooks A.G.; RT "The interaction of KIR3DL1*001 with HLA class I molecules is dependent RT upon molecular microarchitecture within the Bw4 epitope."; RL J. Immunol. 194:781-789(2015). RN [73] RP INTERACTION WITH THE PEPTIDE-LOADING COMPLEX. RX PubMed=26416272; DOI=10.4049/jimmunol.1501515; RA Fleischmann G., Fisette O., Thomas C., Wieneke R., Tumulka F., RA Schneeweiss C., Springer S., Schaefer L.V., Tampe R.; RT "Mechanistic Basis for Epitope Proofreading in the Peptide-Loading RT Complex."; RL J. Immunol. 195:4503-4513(2015). RN [74] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [75] RP FUNCTION (ALLELE B*46:01), AND INTERACTION WITH KIR2DL3. RX PubMed=28514659; DOI=10.1016/j.celrep.2017.04.059; RA Hilton H.G., McMurtrey C.P., Han A.S., Djaoud Z., Guethlein L.A., RA Blokhuis J.H., Pugh J.L., Goyos A., Horowitz A., Buchli R., Jackson K.W., RA Bardet W., Bushnell D.A., Robinson P.J., Mendoza J.L., Birnbaum M.E., RA Nielsen M., Garcia K.C., Hildebrand W.H., Parham P.; RT "The Intergenic Recombinant HLA-B*46:01 Has a Distinctive Peptidome that RT Includes KIR2DL3 Ligands."; RL Cell Rep. 19:1394-1405(2017). RN [76] RP FUNCTION (ALLELES B*07:02; B*27:05 AND B*40:01). RX PubMed=32887977; DOI=10.1038/s41590-020-0782-6; RG Oxford Immunology Network Covid-19 Response T cell Consortium; RG ISARIC4C Investigators; RA Peng Y., Mentzer A.J., Liu G., Yao X., Yin Z., Dong D., Dejnirattisai W., RA Rostron T., Supasa P., Liu C., Lopez-Camacho C., Slon-Campos J., Zhao Y., RA Stuart D.I., Paesen G.C., Grimes J.M., Antson A.A., Bayfield O.W., RA Hawkins D.E.D.P., Ker D.S., Wang B., Turtle L., Subramaniam K., Thomson P., RA Zhang P., Dold C., Ratcliff J., Simmonds P., de Silva T., Sopp P., RA Wellington D., Rajapaksa U., Chen Y.L., Salio M., Napolitani G., Paes W., RA Borrow P., Kessler B.M., Fry J.W., Schwabe N.F., Semple M.G., Baillie J.K., RA Moore S.C., Openshaw P.J.M., Ansari M.A., Dunachie S., Barnes E., RA Frater J., Kerr G., Goulder P., Lockett T., Levin R., Zhang Y., Jing R., RA Ho L.P., Cornall R.J., Conlon C.P., Klenerman P., Screaton G.R., RA Mongkolsapaya J., McMichael A., Knight J.C., Ogg G., Dong T.; RT "Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK RT convalescent individuals following COVID-19."; RL Nat. Immunol. 21:1336-1345(2020). RN [77] RP FUNCTION (ALLELE B*57:01). RX PubMed=34228645; DOI=10.1172/jci148979; RA Bansal A., Gehre M.N., Qin K., Sterrett S., Ali A., Dang Y., Abraham S., RA Costanzo M.C., Venegas L.A., Tang J., Manjunath N., Brockman M.A., RA Yang O.O., Kan-Mitchell J., Goepfert P.A.; RT "HLA-E-restricted HIV-1-specific CD8+ T cell responses in natural RT infection."; RL J. Clin. Invest. 131:0-0(2021). RN [78] RP DOMAIN, AND POLYMORPHISM. RX PubMed=37264229; DOI=10.1038/s41590-023-01523-z; RA Lin Z., Bashirova A.A., Viard M., Garner L., Quastel M., Beiersdorfer M., RA Kasprzak W.K., Akdag M., Yuki Y., Ojeda P., Das S., Andresson T., RA Naranbhai V., Horowitz A., McMichael A.J., Hoelzemer A., Gillespie G.M., RA Garcia-Beltran W.F., Carrington M.; RT "HLA class I signal peptide polymorphism determines the level of CD94/NKG2- RT HLA-E-mediated regulation of effector cell responses."; RL Nat. Immunol. 24:1087-1097(2023). RN [79] RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-300 (ALLELE B*27:05) IN RP COMPLEX WITH B2M AND PEPTIDE, AND FUNCTION (ALLELE B*27:05). RX PubMed=15657948; DOI=10.1002/eji.200425724; RA Stewart-Jones G.B., di Gleria K., Kollnberger S., McMichael A.J., RA Jones E.Y., Bowness P.; RT "Crystal structures and KIR3DL1 recognition of three immunodominant viral RT peptides complexed to HLA-B*2705."; RL Eur. J. Immunol. 35:341-351(2005). RN [80] RP X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 25-300 (ALLELE B*15:01) IN RP COMPLEX WITH EBV NUCLEAR ANTIGEN AND UBE2 PEPTIDES, AND DISULFIDE BONDS. RX PubMed=17057332; DOI=10.1107/s0907444906027636; RA Roder G., Blicher T., Justesen S., Johannesen B., Kristensen O., RA Kastrup J., Buus S., Gajhede M.; RT "Crystal structures of two peptide-HLA-B*1501 complexes; structural RT characterization of the HLA-B62 supertype."; RL Acta Crystallogr. D 62:1300-1310(2006). RN [81] RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 25-299 (ALLELE B*57:01) IN RP COMPLEX WITH B2M AND SELF-PEPTIDE, INTERACTION WITH KIR3DL1, DOMAIN, BW4 RP MOTIF, AND FUNCTION (ALLELE B*57:01). RX PubMed=22020283; DOI=10.1038/nature10517; RA Vivian J.P., Duncan R.C., Berry R., O'Connor G.M., Reid H.H., Beddoe T., RA Gras S., Saunders P.M., Olshina M.A., Widjaja J.M., Harpur C.M., Lin J., RA Maloveste S.M., Price D.A., Lafont B.A., McVicar D.W., Clements C.S., RA Brooks A.G., Rossjohn J.; RT "Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of RT human leukocyte antigen B."; RL Nature 479:401-405(2011). RN [82] RP X-RAY CRYSTALLOGRAPHY (2.99 ANGSTROMS) OF 25-300 (ALLELE B*51:01) IN RP COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, AND FUNCTION (ALLELE RP B*51:01). RX PubMed=24600035; DOI=10.4049/jimmunol.1302667; RA Motozono C., Kuse N., Sun X., Rizkallah P.J., Fuller A., Oka S., Cole D.K., RA Sewell A.K., Takiguchi M.; RT "Molecular basis of a dominant T cell response to an HIV reverse RT transcriptase 8-mer epitope presented by the protective allele HLA- RT B*51:01."; RL J. Immunol. 192:3428-3434(2014). RN [83] RP X-RAY CRYSTALLOGRAPHY (1.59 ANGSTROMS) OF 25-300 (ALLELE B*07:02) IN RP COMPLEX WITH B2M AND HIV-1 PEPTIDES, DISULFIDE BOND, FUNCTION (ALLELE RP B*07:02), AND DOMAIN. RX PubMed=25808313; DOI=10.1186/s12977-015-0149-5; RA Kloverpris H.N., Cole D.K., Fuller A., Carlson J., Beck K., RA Schauenburg A.J., Rizkallah P.J., Buus S., Sewell A.K., Goulder P.; RT "A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes RT shapes differential HLA-restricted escape."; RL Retrovirology 12:20-20(2015). RN [84] RP X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) (ALLELE B*07:02) IN COMPLEX WITH B2M RP AND PEPTIDE, DISULFIDE BOND, INTERACTION WITH TCR, AND FUNCTION (ALLELE RP B*07:02). RX PubMed=29531227; DOI=10.1038/s41467-018-03321-w; RA Chan K.F., Gully B.S., Gras S., Beringer D.X., Kjer-Nielsen L., Cebon J., RA McCluskey J., Chen W., Rossjohn J.; RT "Divergent T-cell receptor recognition modes of a HLA-I restricted extended RT tumour-associated peptide."; RL Nat. Commun. 9:1026-1026(2018). RN [85] RP ASSOCIATION WITH ABACAVIR HYPERSENSITIVITY. RX PubMed=11888582; DOI=10.1016/s0140-6736(02)07873-x; RA Mallal S., Nolan D., Witt C., Masel G., Martin A.M., Moore C., Sayer D., RA Castley A., Mamotte C., Maxwell D., James I., Christiansen F.T.; RT "Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and RT hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir."; RL Lancet 359:727-732(2002). RN [86] RP ASSOCIATION WITH SPDA1, AND POSSIBLE PROTECTIVE ROLE OF ALLELE B*27:07. RX PubMed=15603872; DOI=10.1016/j.humimm.2004.08.177; RA Varnavidou-Nicolaidou A., Karpasitou K., Georgiou D., Stylianou G., RA Kokkofitou A., Michalis C., Constantina C., Gregoriadou C., Kyriakides G.; RT "HLA-B27 in the Greek Cypriot population: distribution of subtypes in RT patients with ankylosing spondylitis and other HLA-B27-related diseases. RT The possible protective role of B*2707."; RL Hum. Immunol. 65:1451-1454(2004). RN [87] RP ASSOCIATION OF ALLELE B*15:02 WITH STEVENS-JOHNSON SYNDROME. RX PubMed=15057820; DOI=10.1038/428486a; RA Chung W.-H., Hung S.-I., Hong H.-S., Hsih M.-S., Yang L.-C., Ho H.-C., RA Wu J.-Y., Chen Y.-T.; RT "Medical genetics: a marker for Stevens-Johnson syndrome."; RL Nature 428:486-486(2004). RN [88] RP INVOLVEMENT IN RA, ASSOCIATION OF ALLELE GROUP B*8 WITH RHEUMATOID RP ARTHRITIS, AND VARIANT ASP-33. RX PubMed=22286218; DOI=10.1038/ng.1076; RA Raychaudhuri S., Sandor C., Stahl E.A., Freudenberg J., Lee H.S., Jia X., RA Alfredsson L., Padyukov L., Klareskog L., Worthington J., Siminovitch K.A., RA Bae S.C., Plenge R.M., Gregersen P.K., de Bakker P.I.; RT "Five amino acids in three HLA proteins explain most of the association RT between MHC and seropositive rheumatoid arthritis."; RL Nat. Genet. 44:291-296(2012). RN [89] RP ASSOCIATION OF ALLELE GROUP B*51 WITH BEHCET DISEASE. RX PubMed=23291587; DOI=10.1038/ng.2520; RA Kirino Y., Bertsias G., Ishigatsubo Y., Mizuki N., Tugal-Tutkun I., RA Seyahi E., Ozyazgan Y., Sacli F.S., Erer B., Inoko H., Emrence Z., RA Cakar A., Abaci N., Ustek D., Satorius C., Ueda A., Takeno M., Kim Y., RA Wood G.M., Ombrello M.J., Meguro A., Guel A., Remmers E.F., Kastner D.L.; RT "Genome-wide association analysis identifies new susceptibility loci for RT Behcet's disease and epistasis between HLA-B*51 and ERAP1."; RL Nat. Genet. 45:202-207(2013). RN [90] RP POLYMORPHISM. RX PubMed=28650991; DOI=10.1371/journal.pgen.1006862; RA Robinson J., Guethlein L.A., Cereb N., Yang S.Y., Norman P.J., RA Marsh S.G.E., Parham P.; RT "Distinguishing functional polymorphism from random variation in the RT sequences of >10,000 HLA-A, -B and -C alleles."; RL PLoS Genet. 13:E1006862-E1006862(2017). CC -!- FUNCTION: Antigen-presenting major histocompatibility complex class I CC (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays CC primarily viral and tumor-derived peptides on antigen-presenting cells CC for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CC CD8-positive T cells, guiding antigen-specific T cell immune response CC to eliminate infected or transformed cells (PubMed:25808313, CC PubMed:29531227, PubMed:9620674, PubMed:23209413). May also present CC self-peptides derived from the signal sequence of secreted or membrane CC proteins, although T cells specific for these peptides are usually CC inactivated to prevent autoreactivity (PubMed:7743181, CC PubMed:18991276). Both the peptide and the MHC molecule are recognized CC by TCR, the peptide is responsible for the fine specificity of antigen CC recognition and MHC residues account for the MHC restriction of T cells CC (PubMed:29531227, PubMed:9620674, PubMed:24600035). Typically presents CC intracellular peptide antigens of 8 to 13 amino acids that arise from CC cytosolic proteolysis via constitutive proteasome and IFNG-induced CC immunoproteasome (PubMed:23209413). Can bind different peptides CC containing allele-specific binding motifs, which are mainly defined by CC anchor residues at position 2 and 9 (PubMed:25808313, PubMed:29531227). CC {ECO:0000269|PubMed:18991276, ECO:0000269|PubMed:23209413, CC ECO:0000269|PubMed:24600035, ECO:0000269|PubMed:25808313, CC ECO:0000269|PubMed:29531227, ECO:0000269|PubMed:7743181, CC ECO:0000269|PubMed:9620674}. CC -!- FUNCTION: Allele B*07:02: Displays peptides sharing a common signature CC motif, namely a Pro residue at position 2 and mainly a Leu anchor CC residue at the C-terminus (PubMed:7743181). Presents a long peptide CC (APRGPHGGAASGL) derived from the cancer-testis antigen CTAG1A/NY-ESO-1, CC eliciting a polyclonal CD8-positive T cell response against tumor cells CC (PubMed:29531227). Presents viral epitopes derived from HIV-1 gag-pol CC (TPQDLNTML) and Nef (RPQVPLRPM) (PubMed:25808313). Presents an CC immunodominant epitope derived from SARS-CoV-2 N/nucleoprotein CC (SPRWYFYYL) (PubMed:32887977). Displays self-peptides including a CC peptide derived from the signal sequence of HLA-DPB1 (APRTVALTA) CC (PubMed:7743181). {ECO:0000269|PubMed:25808313, CC ECO:0000269|PubMed:29531227, ECO:0000269|PubMed:32887977, CC ECO:0000269|PubMed:7743181}. CC -!- FUNCTION: Allele B*08:01: Presents to CD8-positive T cells viral CC epitopes derived from EBV/HHV-4 EBNA3 (QAKWRLQTL), eliciting cytotoxic CC T cell response. {ECO:0000269|PubMed:9620674}. CC -!- FUNCTION: Allele B*13:02: Presents multiple HIV-1 epitopes derived from CC gag (RQANFLGKI, GQMREPRGSDI), nef (RQDILDLWI), gag-pol (RQYDQILIE, CC GQGQWTYQI) and rev (LQLPPLERL), all having in common a Gln residue at CC position 2 and mainly hydrophobic amino acids Leu, Ile or Val at the C- CC terminus. Associated with succesful control of HIV-1 infection. CC {ECO:0000269|PubMed:17251285}. CC -!- FUNCTION: Allele B*18:01: Preferentially presents octomeric and CC nonameric peptides sharing a common motif, namely a Glu at position 2 CC and Phe or Tyr anchor residues at the C-terminus (PubMed:14978097, CC PubMed:23749632, PubMed:18991276). Presents an EBV/HHV-4 epitope CC derived from BZLF1 (SELEIKRY) (PubMed:23749632). May present to CD8- CC positive T cells an antigenic peptide derived from MAGEA3 (MEVDPIGHLY), CC triggering an anti-tumor immune response (PubMed:12366779). May display CC a broad repertoire of self-peptides with a preference for peptides CC derived from RNA-binding proteins (PubMed:14978097). CC {ECO:0000269|PubMed:12366779, ECO:0000269|PubMed:14978097, CC ECO:0000269|PubMed:18991276, ECO:0000269|PubMed:23749632}. CC -!- FUNCTION: Allele B*27:05: Presents to CD8-positive T cells CC immunodominant viral epitopes derived from HCV POLG (ARMILMTHF), HIV-1 CC gag (KRWIILGLNK), IAV NP (SRYWAIRTR), SARS-CoV-2 N/nucleoprotein CC (QRNAPRITF), EBV/HHV-4 EBNA4 (HRCQAIRKK) and EBV/HHV-4 EBNA6 CC (RRIYDLIEL), conferring longterm protection against viral infection CC (PubMed:19139562, PubMed:18385228, PubMed:15113903, PubMed:9620674, CC PubMed:32887977). Can present self-peptides derived from cytosolic and CC nuclear proteins. All peptides carry an Arg at position 2 CC (PubMed:1922338). The peptide-bound form interacts with NK cell CC inhibitory receptor KIR3DL1 and inhibits NK cell activation in a CC peptide-specific way, being particularly sensitive to the nature of the CC amino acid side chain at position 8 of the antigenic peptide CC (PubMed:8879234, PubMed:15657948). KIR3DL1 fails to recognize HLA- CC B*27:05 in complex with B2M and EBV/HHV-4 EBNA6 (RRIYDLIEL) peptide, CC which can lead to increased activation of NK cells during infection CC (PubMed:15657948). May present an altered repertoire of peptides in the CC absence of TAP1-TAP2 and TAPBPL (PubMed:9620674). CC {ECO:0000269|PubMed:15113903, ECO:0000269|PubMed:15657948, CC ECO:0000269|PubMed:18385228, ECO:0000269|PubMed:19139562, CC ECO:0000269|PubMed:1922338, ECO:0000269|PubMed:8879234, CC ECO:0000269|PubMed:9620674}. CC -!- FUNCTION: Allele B*40:01: Presents immunodominant viral epitopes CC derived from EBV/HHV-4 LMP2 (IEDPPFNSL) and SARS-CoV-2 N/nucleoprotein CC (MEVTPSGTWL), triggering memory CD8-positive T cell response CC (PubMed:18991276, PubMed:32887977). Displays self-peptides sharing a CC signature motif, namely a Glu at position 2 and a Leu anchor residue at CC the C-terminus (PubMed:18991276). {ECO:0000269|PubMed:18991276, CC ECO:0000269|PubMed:32887977}. CC -!- FUNCTION: Allele B*41:01: Displays self-peptides sharing a signature CC motif, namely a Glu at position 2 and Ala or Pro anchor residues at the CC C-terminus. {ECO:0000269|PubMed:18991276}. CC -!- FUNCTION: Allele B*44:02: Presents immunodominant viral epitopes CC derived from EBV/HHV-4 EBNA4 (VEITPYKPTW) and EBNA6 (AEGGVGWRHW, CC EENLLDFVRF), triggering memory CD8-positive T cell response CC (PubMed:9620674, PubMed:18991276). Displays self-peptides sharing a CC signature motif, namely a Glu at position 2 and Phe, Tyr or Trp anchor CC residues at the C-terminus (PubMed:18991276). CC {ECO:0000269|PubMed:18991276, ECO:0000269|PubMed:9620674}. CC -!- FUNCTION: Allele B*45:01: Displays self-peptides sharing a signature CC motif, namely a Glu at position 2 and Ala or Pro anchor residues at the CC C-terminus. {ECO:0000269|PubMed:18991276}. CC -!- FUNCTION: Allele B*46:01: Preferentially presents nonameric peptides CC sharing a signature motif, namely Ala and Leu at position 2 and Tyr, CC Phe, Leu, or Met anchor residues at the C-terminus. The peptide-bound CC form interacts with KIR2DL3 and inhibits NK cell cytotoxic response in CC a peptide-specific way. {ECO:0000269|PubMed:28514659}. CC -!- FUNCTION: Allele B*47:01: Displays self-peptides sharing a signature CC motif, namely an Asp at position 2 and Leu or Met anchor residues at CC the C-terminus. {ECO:0000269|PubMed:18991276}. CC -!- FUNCTION: Allele B*49:01: Displays self-peptides sharing a signature CC motif, namely a Glu at position 2 and Ile or Val anchor residues at the CC C-terminus. {ECO:0000269|PubMed:18991276}. CC -!- FUNCTION: Allele B*50:01: Displays self-peptides sharing a signature CC motif, namely a Glu at position 2 and Ala or Pro anchor residues at the CC C-terminus. {ECO:0000269|PubMed:18991276}. CC -!- FUNCTION: Allele B*51:01: Presents an octomeric HIV-1 epitope derived CC from gag-pol (TAFTIPSI) to the public TRAV17/TRBV7-3 TCR clonotype, CC strongly suppressing HIV-1 replication. {ECO:0000269|PubMed:24600035}. CC -!- FUNCTION: Allele B*54:01: Displays peptides sharing a common signature CC motif, namely a Pro residue at position 2 and Ala anchor residue at the CC C-terminus. {ECO:0000269|PubMed:7743181}. CC -!- FUNCTION: Allele B*55:01: Displays peptides sharing a common signature CC motif, namely a Pro residue at position 2 and Ala anchor residue at the CC C-terminus. {ECO:0000269|PubMed:7743181}. CC -!- FUNCTION: Allele B*56:01: Displays peptides sharing a common signature CC motif, namely a Pro residue at position 2 and Ala anchor residue at the CC C-terminus. {ECO:0000269|PubMed:7743181}. CC -!- FUNCTION: Allele B*57:01: The peptide-bound form recognizes KIR3DL1 and CC inhibits NK cell cytotoxic response. Presents HIV gag peptides CC (immunodominant KAFSPEVIPMF and subdominant KALGPAATL epitopes) CC predominantly to CD8-positive T cell clones expressing a TRAV41- CC containing TCR, triggering HLA-B-restricted T cell responses. CC {ECO:0000269|PubMed:22020283, ECO:0000269|PubMed:25480565, CC ECO:0000269|PubMed:34228645}. CC -!- FUNCTION: Allele B*67:01: Displays peptides sharing a common signature CC motif, namely a Pro residue at position 2 and Leu anchor residue at the CC C-terminus. {ECO:0000269|PubMed:7743181}. CC -!- SUBUNIT: Heterotrimer that consists of an alpha chain HLA-B, a beta CC chain B2M and a peptide (peptide-HLA-B-B2M) (PubMed:25808313, CC PubMed:29531227, PubMed:15657948, PubMed:17057332, PubMed:22020283, CC PubMed:24600035). Early in biogenesis, HLA-B-B2M dimer interacts with CC the components of the peptide-loading complex composed of TAPBP, TAP1- CC TAP2, TAPBPL, PDIA3/ERP57 and CALR (PubMed:9036970, PubMed:9620674, CC PubMed:26439010, PubMed:26416272). Interacts with TAP1-TAP2 transporter CC via TAPBP; this interaction is obligatory for the loading of peptide CC epitopes delivered to the ER by TAP1-TAP2 transporter (PubMed:9036970, CC PubMed:9620674). Interacts with TAPBPL; TAPBPL binds peptide-free HLA- CC B-B2M complexes or those loaded with low affinity peptides, likely CC facilitating peptide exchange for higher affinity peptides CC (PubMed:26439010). Only optimally assembled peptide-HLA-B-B2M trimer CC translocates to the surface of antigen-presenting cells, where it CC interacts with TCR and CD8 coreceptor on the surface of T cells. HLA-B CC (via polymorphic alpha-1 and alpha-2 domains) interacts with antigen- CC specific TCR (via CDR1, CDR2 and CDR3 domains) (PubMed:29531227, CC PubMed:24600035). One HLA-B molecule (mainly via nonpolymorphic alpha-3 CC domain) interacts with one CD8A homodimer (via CDR-like loop); this CC interaction ensures peptide-HLA-B-B2M recognition by CD8-positive T CC cells only (PubMed:29531227). Allele B*57:01 interacts (via Bw4 motif) CC with KIR3DL1 (via Ig-like C2-type domain); this interaction may CC interfere with peptide binding (PubMed:22020283, PubMed:25480565). CC Allele B*46:01 interacts with KIR2DL3 (PubMed:28514659). CC {ECO:0000269|PubMed:15657948, ECO:0000269|PubMed:17057332, CC ECO:0000269|PubMed:22020283, ECO:0000269|PubMed:24600035, CC ECO:0000269|PubMed:25480565, ECO:0000269|PubMed:25808313, CC ECO:0000269|PubMed:26416272, ECO:0000269|PubMed:26439010, CC ECO:0000269|PubMed:28514659, ECO:0000269|PubMed:29531227, CC ECO:0000269|PubMed:9036970, ECO:0000269|PubMed:9620674}. CC -!- SUBUNIT: (Microbial infection) Interacts with HTLV-1 accessory protein CC p12I. {ECO:0000269|PubMed:11390610}. CC -!- INTERACTION: CC P01889; P43626: KIR2DL1; NbExp=2; IntAct=EBI-1046513, EBI-8684277; CC P01889; P43628: KIR2DL3; NbExp=2; IntAct=EBI-1046513, EBI-8632435; CC P01889; P43632: KIR2DS4; NbExp=2; IntAct=EBI-1046513, EBI-13916812; CC P01889; P43629: KIR3DL1; NbExp=3; IntAct=EBI-1046513, EBI-3910993; CC P01889; Q14943: KIR3DS1; NbExp=7; IntAct=EBI-1046513, EBI-15316524; CC P01889; Q8N423: LILRB2; NbExp=7; IntAct=EBI-1046513, EBI-2816428; CC P01889; Q9BX59: TAPBPL; NbExp=3; IntAct=EBI-1046513, EBI-12017416; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:25480565, CC ECO:0000269|PubMed:26439010, ECO:0000269|PubMed:9620674}; Single-pass CC type I membrane protein {ECO:0000255}. Endoplasmic reticulum membrane CC {ECO:0000305|PubMed:9620674}; Single-pass type I membrane protein CC {ECO:0000255}. CC -!- DOMAIN: The alpha-1 domain is a structural part of the peptide-binding CC cleft (PubMed:25808313). Residues 101-107 determine Bw4/Bw6 motifs, CC which serologically distinguish HLA-B alleles. Each HLA-B allele CC posseses either the Bw4 or Bw6 motif. Only HLA-B alleles bearing the CC Bw4 epitope are recognized by NK cell inhibitory receptor KIR3DL1 CC (PubMed:25480565, PubMed:22020283). {ECO:0000269|PubMed:22020283, CC ECO:0000269|PubMed:25480565, ECO:0000269|PubMed:25808313}. CC -!- DOMAIN: The alpha-2 domain is a structural part of the peptide-binding CC cleft (PubMed:25808313). Mediates the interaction with TAP1-TAP2 CC complex (By similarity). {ECO:0000250|UniProtKB:P04439, CC ECO:0000269|PubMed:25808313}. CC -!- DOMAIN: The alpha-3 Ig-like domain mediates the interaction with CD8 CC coreceptor. {ECO:0000250|UniProtKB:P04439}. CC -!- DOMAIN: The VL9 peptide/epitope (VMAPRT[V/L][L/V/I/F]L) derived from CC the signal sequence is loaded onto HLA-E and enables HLA-E expression CC at the plasma membrane. Distinct VL9 peptides presented by HLA-E CC variably affect its recognition by KLRD1-KLRC1 or KLRD1-KLRC2 receptors CC on NK cells. Most HLA-B allotypes contain VL9 peptides with low CC affinity for HLA-E. The VL9 peptide derived from HLA-B*07, B*08, B*14, CC B*38, B*39, B*42 and B*48 allotypes, displays high affinity for HLA-E CC yet fails to drive NK cell activation. It outcompetes other VL9 CC peptides derived from HLA-A and HLA-C for binding to HLA-E, lowering CC the threshold of NK cell activation. {ECO:0000269|PubMed:37264229}. CC -!- POLYMORPHISM: The most polymorphic of the mammalian genome. Polymorphic CC residues encode for alpha-1 and alpha-2 domains of the peptide-binding CC cleft, where they contribute to variations in peptide binding and TCR CC recognition among different alleles. The human population is estimated CC to have millions of HLA-B alleles. But only 17 common HLA-A alleles are CC considered core alleles, representing all functionally significant CC variation (polymorphism) in alpha-1 and alpha-2 domains. These are: CC B*07:02; B*08:01; B*13:02; B*15:01; B*18:01; B*27:05; B*35:01; B*37:01; CC B*38:01; B*40:01; B*44:02; B*45:01; B*51:01; B*54:01; B*57:01 and CC B*73:01. Among these, B*07:02; B*15:01; B*18:01; B*37:01; B*51:01; CC B*54:01; B*57:01 and B*73:01, were likely passed by introgression from CC archaic to modern humans. Functional alleles of more recent origin CC (non-core) were derived by recombination (PubMed:28650991). The CC sequence shown is that of B*07:02. The sequences of core alleles and CC common representative alleles of serologically distinct allele groups CC are described as variants of B*07:02. Allelic variations of HLA-B CC signal peptide regulate HLA-E recognition by KLRD1-KLRC1 and KLRD1- CC KLRC2 receptors in viral infection and tumorigenesis by affecting its CC processing and by changing the affinity of HLA-E-VL9 complex for KLRD1- CC KLRC1 and KLRD1-KLRC2 receptors. {ECO:0000269|PubMed:28650991, CC ECO:0000269|PubMed:37264229}. CC -!- DISEASE: Stevens-Johnson syndrome (SJS) [MIM:608579]: A rare blistering CC mucocutaneous disease that share clinical and histopathologic features CC with toxic epidermal necrolysis. Both disorders are characterized by CC high fever, malaise, and a rapidly developing blistering exanthema of CC macules and target-like lesions accompanied by mucosal involvement. CC Stevens-Johnson syndrome is a milder disease characterized by CC destruction and detachment of the skin epithelium and mucous membranes CC involving less than 10% of the body surface area. Ocular symptoms CC include ulcerative conjunctivitis, keratitis, iritis, uveitis and CC sometimes blindness. It can be caused by a severe adverse reaction to CC particular types of medication, although Mycoplasma infections may CC induce some cases. Note=Disease susceptibility is associated with CC variants affecting the gene represented in this entry. Increased CC susceptibility to Stevens-Johnson syndrome is conferred by allele CC B*15:02. {ECO:0000269|PubMed:15057820}. CC -!- DISEASE: Spondyloarthropathy 1 (SPDA1) [MIM:106300]: A chronic CC rheumatic disease with multifactorial inheritance. It includes a CC spectrum of related disorders comprising ankylosing spondylitis, a CC subset of psoriatic arthritis, reactive arthritis (e.g. Reiter CC syndrome), arthritis associated with inflammatory bowel disease and CC undifferentiated spondyloarthropathy. These disorders may occur CC simultaneously or sequentially in the same patient, probably CC representing various phenotypic expressions of the same disease. CC Ankylosing spondylitis is the form of rheumatoid arthritis affecting CC the spine and is considered the prototype of seronegative CC spondyloarthropathies. It produces pain and stiffness as a result of CC inflammation of the sacroiliac, intervertebral, and costovertebral CC joints. Note=Disease susceptibility is associated with variants CC affecting the gene represented in this entry. A restricted number of CC HLA-B*27 subtypes can be associated with ankylosing spondylitis and CC other B*27-related diseases, and an elevated frequency of the B*27:02 CC allele in ankylosing spondylitis patients is identified. The allele CC B*27:07 seems to have a protective role in some populations because it CC was found only in the healthy controls. {ECO:0000269|PubMed:15603872}. CC -!- DISEASE: Note=There is evidence that HLA-B*51 is associated with CC susceptibility to Behcet disease (BD). However, it is not certain CC whether HLA-B*51 itself or a closely linked gene is responsible for CC susceptibility. The world distribution of HLA-B*51 in healthy people CC corresponds to the global distribution of BD; in Southern hemisphere CC countries (Africa, South Pacific, etc.) and in some parts of Europe, CC the prevalence of HLA-B*51 in healthy people is low or null, CC corresponding to a low prevalence of BD. The wide variation that exists CC in the relative risk of HLA-B*51 would support other nongenetic risk CC factors. {ECO:0000269|PubMed:23291587}. CC -!- DISEASE: Note=The presence of allele B*57:01 is associated with CC increased susceptibility to abacavir hypersensitivity [MIM:142830] in CC HIV-1 patients. {ECO:0000269|PubMed:11888582}. CC -!- DISEASE: Note=Allele group B*08 is associated with increased CC susceptibility to rheumatoid arthritis, where affected individuals have CC antibodies to cyclic citrullinated peptide (anti-CCP-positive CC rheumatoid arthritis). {ECO:0000269|PubMed:22286218}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U03698; AAA03719.1; -; mRNA. DR EMBL; M32317; AAA36230.1; -; mRNA. DR EMBL; M32320; AAA36233.1; -; mRNA. DR EMBL; M32319; AAA36232.1; -; mRNA. DR EMBL; M32318; AAA36231.1; -; mRNA. DR EMBL; M77774; AAA03686.1; -; mRNA. DR EMBL; M77778; AAA03687.1; -; mRNA. DR EMBL; M77776; AAA03689.1; -; mRNA. DR EMBL; X61710; CAA43879.1; -; mRNA. DR EMBL; X61706; CAA43875.1; -; mRNA. DR EMBL; X61708; CAA43877.1; -; mRNA. DR EMBL; M24037; AAA02950.1; -; mRNA. DR EMBL; M84380; AAA59629.1; -; mRNA. DR EMBL; L09736; AAA36224.1; -; mRNA. DR EMBL; D14343; BAA03277.1; -; mRNA. DR EMBL; M83193; AAA58628.1; -; mRNA. DR EMBL; L07743; AAA59621.1; -; mRNA. DR EMBL; X77658; CAA54739.1; -; mRNA. DR EMBL; U03859; AAA03601.1; -; mRNA. DR EMBL; U04787; AAA53175.1; -; mRNA. DR EMBL; L24373; AAA96733.1; -; mRNA. DR EMBL; D50291; BAA08822.1; -; mRNA. DR EMBL; L37880; AAC41941.1; -; mRNA. DR EMBL; L36591; AAA73509.1; -; mRNA. DR EMBL; U04243; AAA87396.1; -; mRNA. DR EMBL; X90390; CAA62035.1; -; mRNA. DR EMBL; U36492; AAB18369.1; -; mRNA. DR EMBL; D50292; BAA08823.1; -; mRNA. DR EMBL; AB008102; BAA22916.1; -; mRNA. DR EMBL; M11799; AAA59628.1; -; Genomic_DNA. DR EMBL; X03665; CAA27302.1; -; Genomic_DNA. DR EMBL; X03666; CAA27302.1; JOINED; Genomic_DNA. DR EMBL; M14013; AAA59643.1; -; Genomic_DNA. DR EMBL; M19757; AAA52657.1; -; Genomic_DNA. DR EMBL; M19756; AAA52664.1; -; Genomic_DNA. DR EMBL; M28115; AAA59617.1; -; Genomic_DNA. DR EMBL; M28109; AAA59617.1; JOINED; Genomic_DNA. DR EMBL; M28110; AAA59617.1; JOINED; Genomic_DNA. DR EMBL; M28111; AAA59617.1; JOINED; Genomic_DNA. DR EMBL; M28112; AAA59617.1; JOINED; Genomic_DNA. DR EMBL; M28113; AAA59617.1; JOINED; Genomic_DNA. DR EMBL; M28114; AAA59617.1; JOINED; Genomic_DNA. DR EMBL; L41087; AAA64513.1; -; Genomic_DNA. DR EMBL; L41086; AAA64513.1; JOINED; Genomic_DNA. DR EMBL; M24036; AAA52662.1; -; Genomic_DNA. DR EMBL; M24041; AAA59660.1; -; Genomic_DNA. DR EMBL; M24040; AAA59661.1; -; Genomic_DNA. DR EMBL; M24035; AAA59666.1; -; Genomic_DNA. DR EMBL; M24039; AAA59662.1; -; Genomic_DNA. DR EMBL; M24034; AAA59667.1; -; Genomic_DNA. DR EMBL; M24038; AAA59663.1; -; Genomic_DNA. DR EMBL; M24033; AAA59665.1; -; mRNA. DR EMBL; M58636; AAA36228.1; -; Genomic_DNA. DR EMBL; M33573; AAA59644.1; -; Genomic_DNA. DR EMBL; X55711; CAA39244.1; -; Genomic_DNA. DR EMBL; M94053; AAA52659.1; -; Genomic_DNA. DR EMBL; L41628; AAA65040.1; -; Genomic_DNA. DR EMBL; L17005; AAC37548.1; -; mRNA. DR EMBL; AJ292075; CAC33440.1; -; Genomic_DNA. DR EMBL; AJ295294; CAC18876.1; -; Genomic_DNA. DR EMBL; AJ310507; CAC34572.1; -; Genomic_DNA. DR EMBL; AJ309193; CAC38392.1; -; Genomic_DNA. DR EMBL; AJ309194; CAC38393.1; -; Genomic_DNA. DR EMBL; AJ458992; CAD30340.1; -; Genomic_DNA. DR EMBL; AJ310508; CAC34573.1; -; Genomic_DNA. DR EMBL; AJ308398; CAC33087.2; -; Genomic_DNA. DR EMBL; AJ309139; CAC38066.1; -; Genomic_DNA. DR EMBL; AJ310509; CAC34574.1; -; Genomic_DNA. DR EMBL; HM543719; ADU18071.1; -; Genomic_DNA. DR EMBL; HM543720; ADU18072.1; -; Genomic_DNA. DR EMBL; JF974053; AEN79482.1; -; Genomic_DNA. DR EMBL; U11267; AAA19927.1; -; mRNA. DR EMBL; U11261; AAA19921.1; -; mRNA. DR EMBL; D50300; BAA08829.1; -; mRNA. DR EMBL; U29057; AAA91229.1; -; mRNA. DR EMBL; U38800; AAC99997.1; -; mRNA. DR EMBL; U40498; AAD00010.1; -; mRNA. DR EMBL; AJ309936; CAC33891.1; -; Genomic_DNA. DR EMBL; AJ309047; CAC35468.1; -; Genomic_DNA. DR EMBL; AJ310358; CAC38763.1; -; Genomic_DNA. DR EMBL; AJ309192; CAC38391.1; -; Genomic_DNA. DR EMBL; MG525292; AUM84865.1; -; Genomic_DNA. DR EMBL; AY007140; AAG02001.1; -; mRNA. DR EMBL; BA000025; BAB63309.1; -; Genomic_DNA. DR EMBL; BC007243; AAH07243.1; -; mRNA. DR EMBL; AK313911; BAG36634.1; -; mRNA. DR EMBL; CR759828; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS34394.1; -. DR RefSeq; NP_005505.2; NM_005514.7. DR PDB; 1A1M; X-ray; 2.30 A; A=25-300. DR PDB; 1A1N; X-ray; 2.00 A; A=25-300. DR PDB; 1A1O; X-ray; 2.30 A; A=25-300. DR PDB; 1A9B; X-ray; 3.20 A; A/D=25-301. DR PDB; 1A9E; X-ray; 2.50 A; A=25-301. DR PDB; 1AGB; X-ray; 2.20 A; A=25-300. DR PDB; 1AGC; X-ray; 2.10 A; A=25-300. DR PDB; 1AGD; X-ray; 2.05 A; A=25-300. DR PDB; 1AGE; X-ray; 2.30 A; A=25-300. DR PDB; 1AGF; X-ray; 2.20 A; A=25-300. DR PDB; 1CG9; X-ray; 2.70 A; A=25-301. DR PDB; 1E27; X-ray; 2.20 A; A=25-300. DR PDB; 1E28; X-ray; 3.00 A; A=25-300. DR PDB; 1HSA; X-ray; 2.10 A; A/D=25-300. DR PDB; 1JGD; X-ray; 1.90 A; A=25-300. DR PDB; 1JGE; X-ray; 2.10 A; A=25-300. DR PDB; 1K5N; X-ray; 1.09 A; A=25-300. DR PDB; 1M05; X-ray; 1.90 A; A/C=25-301. DR PDB; 1M6O; X-ray; 1.60 A; A=25-300. DR PDB; 1MI5; X-ray; 2.50 A; A=25-301. DR PDB; 1N2R; X-ray; 1.70 A; A=25-300. DR PDB; 1OF2; X-ray; 2.20 A; A=25-300. DR PDB; 1OGT; X-ray; 1.47 A; A=25-300. DR PDB; 1SYS; X-ray; 2.40 A; A=25-300. DR PDB; 1SYV; X-ray; 1.70 A; A=25-300. DR PDB; 1UXS; X-ray; 1.55 A; A=25-300. DR PDB; 1UXW; X-ray; 1.71 A; A=25-300. DR PDB; 1W0V; X-ray; 2.27 A; A=25-300. DR PDB; 1W0W; X-ray; 2.11 A; A=25-300. DR PDB; 1XH3; X-ray; 1.48 A; A=25-300. DR PDB; 1XR8; X-ray; 2.30 A; A=25-300. DR PDB; 1XR9; X-ray; 1.79 A; A=25-300. DR PDB; 1ZHK; X-ray; 1.60 A; A=25-300. DR PDB; 1ZHL; X-ray; 1.50 A; A=25-300. DR PDB; 1ZSD; X-ray; 1.70 A; A=25-300. DR PDB; 2A83; X-ray; 1.40 A; A=25-300. DR PDB; 2AK4; X-ray; 2.50 A; A/F/K/Q=25-300. DR PDB; 2AXF; X-ray; 1.80 A; A=25-300. DR PDB; 2AXG; X-ray; 2.00 A; A=25-300. DR PDB; 2BSR; X-ray; 2.30 A; A=25-300. DR PDB; 2BSS; X-ray; 2.00 A; A=25-300. DR PDB; 2BST; X-ray; 2.10 A; A=25-300. DR PDB; 2BVO; X-ray; 1.65 A; A=25-300. DR PDB; 2BVP; X-ray; 1.35 A; A=25-300. DR PDB; 2BVQ; X-ray; 2.00 A; A=25-300. DR PDB; 2H6P; X-ray; 1.90 A; A=25-300. DR PDB; 2HJL; X-ray; 1.50 A; A=25-298. DR PDB; 2NW3; X-ray; 1.70 A; A=25-300. DR PDB; 2NX5; X-ray; 2.70 A; A/F/K/Q=25-300. DR PDB; 2RFX; X-ray; 2.50 A; A=25-299. DR PDB; 2YPK; X-ray; 1.95 A; A=25-298. DR PDB; 2YPL; X-ray; 2.40 A; A=25-298. DR PDB; 3B3I; X-ray; 1.86 A; A=25-300. DR PDB; 3B6S; X-ray; 1.80 A; A=25-300. DR PDB; 3BP4; X-ray; 1.85 A; A=25-300. DR PDB; 3BP7; X-ray; 1.80 A; A=25-300. DR PDB; 3BW9; X-ray; 1.75 A; A=25-300. DR PDB; 3BWA; X-ray; 1.30 A; A=25-300. DR PDB; 3C9N; X-ray; 1.87 A; A=25-300. DR PDB; 3CZF; X-ray; 1.20 A; A=25-300. DR PDB; 3D18; X-ray; 1.74 A; A=25-300. DR PDB; 3DTX; X-ray; 2.10 A; A=25-300. DR PDB; 3DX6; X-ray; 1.70 A; A=25-300. DR PDB; 3DX7; X-ray; 1.60 A; A=25-300. DR PDB; 3DX8; X-ray; 2.10 A; A=25-300. DR PDB; 3DXA; X-ray; 3.50 A; A/F/K=25-300. DR PDB; 3FFC; X-ray; 2.80 A; A/F=25-301. DR PDB; 3HCV; X-ray; 1.95 A; A=25-300. DR PDB; 3KPL; X-ray; 1.96 A; A=25-300. DR PDB; 3KPM; X-ray; 1.60 A; A=25-300. DR PDB; 3KPN; X-ray; 2.00 A; A=25-300. DR PDB; 3KPO; X-ray; 2.30 A; A=25-300. DR PDB; 3KPP; X-ray; 1.90 A; A=25-300. DR PDB; 3KPQ; X-ray; 1.84 A; A=25-300. DR PDB; 3KPR; X-ray; 2.60 A; A/F=25-300. DR PDB; 3KPS; X-ray; 2.70 A; A=25-300. DR PDB; 3KWW; X-ray; 2.18 A; A=25-300. DR PDB; 3KXF; X-ray; 3.10 A; A/C/I/K=25-300. DR PDB; 3L3D; X-ray; 1.80 A; A=25-300. DR PDB; 3L3G; X-ray; 2.10 A; A=25-300. DR PDB; 3L3I; X-ray; 1.70 A; A=25-300. DR PDB; 3L3J; X-ray; 2.40 A; A=25-300. DR PDB; 3L3K; X-ray; 2.60 A; A=25-300. DR PDB; 3LKN; X-ray; 2.00 A; A=25-300. DR PDB; 3LKO; X-ray; 1.80 A; A=25-300. DR PDB; 3LKP; X-ray; 1.80 A; A=25-300. DR PDB; 3LKQ; X-ray; 1.80 A; A=25-300. DR PDB; 3LKR; X-ray; 2.00 A; A=25-300. DR PDB; 3LKS; X-ray; 1.90 A; A=25-300. DR PDB; 3LN4; X-ray; 1.30 A; A=25-298. DR PDB; 3LN5; X-ray; 1.90 A; A=25-298. DR PDB; 3LV3; X-ray; 1.94 A; A=25-300. DR PDB; 3MV7; X-ray; 2.00 A; A=25-300. DR PDB; 3MV8; X-ray; 2.10 A; A=25-300. DR PDB; 3MV9; X-ray; 2.70 A; A=25-300. DR PDB; 3SJV; X-ray; 3.10 A; A/F/K/P=25-301. DR PDB; 3SKM; X-ray; 1.80 A; A=25-300. DR PDB; 3SKO; X-ray; 1.60 A; A=25-301. DR PDB; 3SPV; X-ray; 1.30 A; A=25-300. DR PDB; 3UPR; X-ray; 2.00 A; A/C=25-300. DR PDB; 3VCL; X-ray; 1.70 A; A=25-299. DR PDB; 3VFS; X-ray; 1.85 A; A=25-300. DR PDB; 3VFT; X-ray; 1.95 A; A=25-300. DR PDB; 3VFU; X-ray; 1.65 A; A=25-300. DR PDB; 3VFV; X-ray; 1.55 A; A=25-300. DR PDB; 3VFW; X-ray; 2.30 A; A=25-300. DR PDB; 3VH8; X-ray; 1.80 A; A/D=25-299. DR PDB; 3VRI; X-ray; 1.60 A; A=25-300. DR PDB; 3VRJ; X-ray; 1.90 A; A=25-300. DR PDB; 3W39; X-ray; 3.10 A; A/D=25-300. DR PDB; 3WUW; X-ray; 2.00 A; A=25-299. DR PDB; 3X11; X-ray; 2.15 A; A=25-300. DR PDB; 3X12; X-ray; 1.80 A; A=25-300. DR PDB; 3X13; X-ray; 1.80 A; A=25-300. DR PDB; 3X14; X-ray; 2.00 A; A=25-300. DR PDB; 4G8G; X-ray; 2.40 A; A=25-300. DR PDB; 4G8I; X-ray; 1.60 A; A=25-300. DR PDB; 4G9D; X-ray; 1.60 A; A=25-300. DR PDB; 4G9F; X-ray; 1.90 A; A=25-300. DR PDB; 4JQV; X-ray; 1.50 A; A=25-302. DR PDB; 4JQX; X-ray; 1.90 A; A=25-302. DR PDB; 4LCY; X-ray; 1.60 A; A/F=25-298. DR PDB; 4LNR; X-ray; 2.00 A; A=25-300. DR PDB; 4MJI; X-ray; 2.99 A; A/F=25-300. DR PDB; 4O2C; X-ray; 1.80 A; A=25-298. DR PDB; 4O2E; X-ray; 1.98 A; A/D=25-298. DR PDB; 4O2F; X-ray; 1.90 A; A/D=25-298. DR PDB; 4PR5; X-ray; 1.80 A; A=25-300. DR PDB; 4PRN; X-ray; 1.65 A; A=25-300. DR PDB; 4QRP; X-ray; 2.90 A; A/F=25-300. DR PDB; 4QRQ; X-ray; 1.70 A; A=25-300. DR PDB; 4QRR; X-ray; 3.00 A; A=25-300. DR PDB; 4QRS; X-ray; 1.40 A; A=25-300. DR PDB; 4QRT; X-ray; 1.40 A; A=25-300. DR PDB; 4QRU; X-ray; 1.60 A; A=25-300. DR PDB; 4U1H; X-ray; 1.59 A; A=25-300. DR PDB; 4U1I; X-ray; 1.92 A; A=25-301. DR PDB; 4U1J; X-ray; 1.38 A; A=25-301. DR PDB; 4U1K; X-ray; 2.09 A; A/D=25-300. DR PDB; 4U1L; X-ray; 2.06 A; A/D=25-300. DR PDB; 4U1M; X-ray; 1.18 A; A=25-301. DR PDB; 4U1N; X-ray; 1.77 A; A=25-301. DR PDB; 4U1S; X-ray; 1.76 A; A=25-301. DR PDB; 4XXC; X-ray; 1.43 A; A=25-303. DR PDB; 5B38; X-ray; 2.30 A; A=25-300. DR PDB; 5B39; X-ray; 2.50 A; A=25-300. DR PDB; 5DEF; X-ray; 1.60 A; A=25-300. DR PDB; 5DEG; X-ray; 1.83 A; A=25-300. DR PDB; 5EO0; X-ray; 1.70 A; A=25-299. DR PDB; 5EO1; X-ray; 1.85 A; A=25-299. DR PDB; 5IB1; X-ray; 1.91 A; A=25-300. DR PDB; 5IB2; X-ray; 1.44 A; A=25-300. DR PDB; 5IB3; X-ray; 1.91 A; A=25-300. DR PDB; 5IB4; X-ray; 1.95 A; A=25-300. DR PDB; 5IB5; X-ray; 2.49 A; A/D=25-300. DR PDB; 5IEH; X-ray; 1.50 A; A=25-300. DR PDB; 5IEK; X-ray; 1.80 A; A=25-300. DR PDB; 5IM7; X-ray; 2.50 A; A/C=25-300. DR PDB; 5INC; X-ray; 2.88 A; A/C=25-300. DR PDB; 5IND; X-ray; 2.13 A; A/C=25-300. DR PDB; 5T6W; X-ray; 1.90 A; A=25-300. DR PDB; 5T6X; X-ray; 1.69 A; A=25-300. DR PDB; 5T6Y; X-ray; 1.76 A; A=25-300. DR PDB; 5T6Z; X-ray; 2.00 A; A=25-300. DR PDB; 5T70; X-ray; 2.10 A; A=25-300. DR PDB; 5TXS; X-ray; 1.70 A; A=25-304. DR PDB; 5U98; X-ray; 2.00 A; A/D=25-300. DR PDB; 5V5L; X-ray; 2.00 A; A/C=25-300. DR PDB; 5V5M; X-ray; 2.88 A; A/C=25-300. DR PDB; 5VUD; X-ray; 2.00 A; A=25-300. DR PDB; 5VUE; X-ray; 1.80 A; A=25-300. DR PDB; 5VUF; X-ray; 1.90 A; A=25-300. DR PDB; 5VWD; X-ray; 1.80 A; A=25-300. DR PDB; 5VWF; X-ray; 1.80 A; A=25-300. DR PDB; 5VWH; X-ray; 1.65 A; A=25-300. DR PDB; 5VWJ; X-ray; 2.00 A; A=25-300. DR PDB; 5VZ5; X-ray; 2.59 A; A=25-304. DR PDB; 5WMN; X-ray; 1.82 A; A/C=25-300. DR PDB; 5WMO; X-ray; 1.62 A; A=25-300. DR PDB; 5WMP; X-ray; 1.60 A; A=25-300. DR PDB; 5WMQ; X-ray; 1.40 A; A=25-300. DR PDB; 5WMR; X-ray; 1.58 A; A=25-300. DR PDB; 5XOS; X-ray; 1.70 A; A=25-300. DR PDB; 5XOT; X-ray; 2.79 A; A=25-300. DR PDB; 6AT5; X-ray; 1.50 A; A=1-362. DR PDB; 6AVF; X-ray; 2.03 A; H=1-362. DR PDB; 6AVG; X-ray; 2.60 A; F/G=1-362. DR PDB; 6BJ2; X-ray; 3.35 A; A=25-300. DR PDB; 6BJ3; X-ray; 1.90 A; A=25-300. DR PDB; 6BJ8; X-ray; 1.75 A; A=25-300. DR PDB; 6BXP; X-ray; 1.45 A; A=25-300. DR PDB; 6BXQ; X-ray; 1.58 A; B=25-300. DR PDB; 6D29; X-ray; 1.88 A; A=25-300. DR PDB; 6D2B; X-ray; 2.04 A; A=25-300. DR PDB; 6D2R; X-ray; 1.83 A; A=25-300. DR PDB; 6D2T; X-ray; 1.90 A; A=25-300. DR PDB; 6MT3; X-ray; 1.21 A; A=25-300. DR PDB; 6MT4; X-ray; 1.55 A; A=25-300. DR PDB; 6MT5; X-ray; 1.55 A; A=25-300. DR PDB; 6MT6; X-ray; 1.31 A; A=25-300. DR PDB; 6MTL; X-ray; 1.35 A; A=25-300. DR PDB; 6MTM; X-ray; 3.00 A; A=25-300. DR PDB; 6P23; X-ray; 1.59 A; A=25-300. DR PDB; 6P27; X-ray; 1.59 A; A=25-300. DR PDB; 6P2C; X-ray; 1.40 A; A=25-300. DR PDB; 6P2F; X-ray; 1.48 A; A=25-300. DR PDB; 6P2S; X-ray; 1.65 A; A=25-300. DR PDB; 6PYJ; X-ray; 1.44 A; A=25-300. DR PDB; 6PYL; X-ray; 1.52 A; A=25-300. DR PDB; 6PYV; X-ray; 1.45 A; A=25-300. DR PDB; 6PYW; X-ray; 1.38 A; A=25-300. DR PDB; 6PZ5; X-ray; 1.53 A; A=25-300. DR PDB; 6UJ7; X-ray; 1.90 A; A/D=25-304. DR PDB; 6UJ8; X-ray; 2.25 A; A/D=25-304. DR PDB; 6UJ9; X-ray; 2.90 A; A=25-304. DR PDB; 6VMX; X-ray; 3.10 A; A/F=25-300. DR PDB; 7LFZ; X-ray; 1.90 A; A=25-299. DR PDB; 7LG0; X-ray; 2.30 A; A=25-299. DR PDB; 7LGD; X-ray; 2.88 A; A/C=25-302. DR PDB; 7LGT; X-ray; 1.97 A; A/C=25-302. DR PDB; 7RZD; X-ray; 1.82 A; A=25-299. DR PDB; 7RZJ; X-ray; 1.80 A; A=25-299. DR PDB; 7S79; X-ray; 1.53 A; A=25-299. DR PDB; 7S7D; X-ray; 1.56 A; A=25-299. DR PDB; 7S7E; X-ray; 2.04 A; A=25-299. DR PDB; 7S7F; X-ray; 1.88 A; A=25-299. DR PDB; 7S8A; X-ray; 2.10 A; A=25-299. DR PDB; 7S8E; X-ray; 1.60 A; A=25-299. DR PDB; 7S8F; X-ray; 1.80 A; A=25-299. DR PDBsum; 1A1M; -. DR PDBsum; 1A1N; -. DR PDBsum; 1A1O; -. DR PDBsum; 1A9B; -. DR PDBsum; 1A9E; -. DR PDBsum; 1AGB; -. DR PDBsum; 1AGC; -. DR PDBsum; 1AGD; -. DR PDBsum; 1AGE; -. DR PDBsum; 1AGF; -. DR PDBsum; 1CG9; -. DR PDBsum; 1E27; -. DR PDBsum; 1E28; -. DR PDBsum; 1HSA; -. DR PDBsum; 1JGD; -. DR PDBsum; 1JGE; -. DR PDBsum; 1K5N; -. DR PDBsum; 1M05; -. DR PDBsum; 1M6O; -. DR PDBsum; 1MI5; -. DR PDBsum; 1N2R; -. DR PDBsum; 1OF2; -. DR PDBsum; 1OGT; -. DR PDBsum; 1SYS; -. DR PDBsum; 1SYV; -. DR PDBsum; 1UXS; -. DR PDBsum; 1UXW; -. DR PDBsum; 1W0V; -. DR PDBsum; 1W0W; -. DR PDBsum; 1XH3; -. DR PDBsum; 1XR8; -. DR PDBsum; 1XR9; -. DR PDBsum; 1ZHK; -. DR PDBsum; 1ZHL; -. DR PDBsum; 1ZSD; -. DR PDBsum; 2A83; -. DR PDBsum; 2AK4; -. DR PDBsum; 2AXF; -. DR PDBsum; 2AXG; -. DR PDBsum; 2BSR; -. DR PDBsum; 2BSS; -. DR PDBsum; 2BST; -. DR PDBsum; 2BVO; -. DR PDBsum; 2BVP; -. DR PDBsum; 2BVQ; -. DR PDBsum; 2H6P; -. DR PDBsum; 2HJL; -. DR PDBsum; 2NW3; -. DR PDBsum; 2NX5; -. DR PDBsum; 2RFX; -. DR PDBsum; 2YPK; -. DR PDBsum; 2YPL; -. DR PDBsum; 3B3I; -. DR PDBsum; 3B6S; -. DR PDBsum; 3BP4; -. DR PDBsum; 3BP7; -. DR PDBsum; 3BW9; -. DR PDBsum; 3BWA; -. DR PDBsum; 3C9N; -. DR PDBsum; 3CZF; -. DR PDBsum; 3D18; -. DR PDBsum; 3DTX; -. DR PDBsum; 3DX6; -. DR PDBsum; 3DX7; -. DR PDBsum; 3DX8; -. DR PDBsum; 3DXA; -. DR PDBsum; 3FFC; -. DR PDBsum; 3HCV; -. DR PDBsum; 3KPL; -. DR PDBsum; 3KPM; -. DR PDBsum; 3KPN; -. DR PDBsum; 3KPO; -. DR PDBsum; 3KPP; -. DR PDBsum; 3KPQ; -. DR PDBsum; 3KPR; -. DR PDBsum; 3KPS; -. DR PDBsum; 3KWW; -. DR PDBsum; 3KXF; -. DR PDBsum; 3L3D; -. DR PDBsum; 3L3G; -. DR PDBsum; 3L3I; -. DR PDBsum; 3L3J; -. DR PDBsum; 3L3K; -. DR PDBsum; 3LKN; -. DR PDBsum; 3LKO; -. DR PDBsum; 3LKP; -. DR PDBsum; 3LKQ; -. DR PDBsum; 3LKR; -. DR PDBsum; 3LKS; -. DR PDBsum; 3LN4; -. DR PDBsum; 3LN5; -. DR PDBsum; 3LV3; -. DR PDBsum; 3MV7; -. DR PDBsum; 3MV8; -. DR PDBsum; 3MV9; -. DR PDBsum; 3SJV; -. DR PDBsum; 3SKM; -. DR PDBsum; 3SKO; -. DR PDBsum; 3SPV; -. DR PDBsum; 3UPR; -. DR PDBsum; 3VCL; -. DR PDBsum; 3VFS; -. DR PDBsum; 3VFT; -. DR PDBsum; 3VFU; -. DR PDBsum; 3VFV; -. DR PDBsum; 3VFW; -. DR PDBsum; 3VH8; -. DR PDBsum; 3VRI; -. DR PDBsum; 3VRJ; -. DR PDBsum; 3W39; -. DR PDBsum; 3WUW; -. DR PDBsum; 3X11; -. DR PDBsum; 3X12; -. DR PDBsum; 3X13; -. DR PDBsum; 3X14; -. DR PDBsum; 4G8G; -. DR PDBsum; 4G8I; -. DR PDBsum; 4G9D; -. DR PDBsum; 4G9F; -. DR PDBsum; 4JQV; -. DR PDBsum; 4JQX; -. DR PDBsum; 4LCY; -. DR PDBsum; 4LNR; -. DR PDBsum; 4MJI; -. DR PDBsum; 4O2C; -. DR PDBsum; 4O2E; -. DR PDBsum; 4O2F; -. DR PDBsum; 4PR5; -. DR PDBsum; 4PRN; -. DR PDBsum; 4QRP; -. DR PDBsum; 4QRQ; -. DR PDBsum; 4QRR; -. DR PDBsum; 4QRS; -. DR PDBsum; 4QRT; -. DR PDBsum; 4QRU; -. DR PDBsum; 4U1H; -. DR PDBsum; 4U1I; -. DR PDBsum; 4U1J; -. DR PDBsum; 4U1K; -. DR PDBsum; 4U1L; -. DR PDBsum; 4U1M; -. DR PDBsum; 4U1N; -. DR PDBsum; 4U1S; -. DR PDBsum; 4XXC; -. DR PDBsum; 5B38; -. DR PDBsum; 5B39; -. DR PDBsum; 5DEF; -. DR PDBsum; 5DEG; -. DR PDBsum; 5EO0; -. DR PDBsum; 5EO1; -. DR PDBsum; 5IB1; -. DR PDBsum; 5IB2; -. DR PDBsum; 5IB3; -. DR PDBsum; 5IB4; -. DR PDBsum; 5IB5; -. DR PDBsum; 5IEH; -. DR PDBsum; 5IEK; -. DR PDBsum; 5IM7; -. DR PDBsum; 5INC; -. DR PDBsum; 5IND; -. DR PDBsum; 5T6W; -. DR PDBsum; 5T6X; -. DR PDBsum; 5T6Y; -. DR PDBsum; 5T6Z; -. DR PDBsum; 5T70; -. DR PDBsum; 5TXS; -. DR PDBsum; 5U98; -. DR PDBsum; 5V5L; -. DR PDBsum; 5V5M; -. DR PDBsum; 5VUD; -. DR PDBsum; 5VUE; -. DR PDBsum; 5VUF; -. DR PDBsum; 5VWD; -. DR PDBsum; 5VWF; -. DR PDBsum; 5VWH; -. DR PDBsum; 5VWJ; -. DR PDBsum; 5VZ5; -. DR PDBsum; 5WMN; -. DR PDBsum; 5WMO; -. DR PDBsum; 5WMP; -. DR PDBsum; 5WMQ; -. DR PDBsum; 5WMR; -. DR PDBsum; 5XOS; -. DR PDBsum; 5XOT; -. DR PDBsum; 6AT5; -. DR PDBsum; 6AVF; -. DR PDBsum; 6AVG; -. DR PDBsum; 6BJ2; -. DR PDBsum; 6BJ3; -. DR PDBsum; 6BJ8; -. DR PDBsum; 6BXP; -. DR PDBsum; 6BXQ; -. DR PDBsum; 6D29; -. DR PDBsum; 6D2B; -. DR PDBsum; 6D2R; -. DR PDBsum; 6D2T; -. DR PDBsum; 6MT3; -. DR PDBsum; 6MT4; -. DR PDBsum; 6MT5; -. DR PDBsum; 6MT6; -. DR PDBsum; 6MTL; -. DR PDBsum; 6MTM; -. DR PDBsum; 6P23; -. DR PDBsum; 6P27; -. DR PDBsum; 6P2C; -. DR PDBsum; 6P2F; -. DR PDBsum; 6P2S; -. DR PDBsum; 6PYJ; -. DR PDBsum; 6PYL; -. DR PDBsum; 6PYV; -. DR PDBsum; 6PYW; -. DR PDBsum; 6PZ5; -. DR PDBsum; 6UJ7; -. DR PDBsum; 6UJ8; -. DR PDBsum; 6UJ9; -. DR PDBsum; 6VMX; -. DR PDBsum; 7LFZ; -. DR PDBsum; 7LG0; -. DR PDBsum; 7LGD; -. DR PDBsum; 7LGT; -. DR PDBsum; 7RZD; -. DR PDBsum; 7RZJ; -. DR PDBsum; 7S79; -. DR PDBsum; 7S7D; -. DR PDBsum; 7S7E; -. DR PDBsum; 7S7F; -. DR PDBsum; 7S8A; -. DR PDBsum; 7S8E; -. DR PDBsum; 7S8F; -. DR AlphaFoldDB; P01889; -. DR SMR; P01889; -. DR BioGRID; 109351; 293. DR IntAct; P01889; 98. DR MINT; P01889; -. DR STRING; 9606.ENSP00000399168; -. DR DrugBank; DB01048; Abacavir. DR DrugBank; DB11294; Coccidioides immitis spherule. DR DrugBank; DB04464; N-Formylmethionine. DR TCDB; 9.A.75.1.3; the mhc ii receptor (mhc2r) family. DR GlyConnect; 1331; 1 N-Linked glycan (1 site). DR GlyConnect; 1332; 8 N-Linked glycans (1 site). DR GlyConnect; 1333; 8 N-Linked glycans (1 site). DR GlyConnect; 1334; 5 N-Linked glycans (1 site). DR GlyConnect; 1335; 2 N-Linked glycans (1 site). DR GlyConnect; 1336; 2 N-Linked glycans (1 site). DR GlyConnect; 1337; 8 N-Linked glycans (1 site). DR GlyConnect; 1338; 2 N-Linked glycans (1 site). DR GlyConnect; 1339; 2 N-Linked glycans (1 site). DR GlyConnect; 1340; 3 N-Linked glycans (1 site). DR GlyConnect; 1341; 8 N-Linked glycans (1 site). DR GlyConnect; 1342; 2 N-Linked glycans (1 site). DR GlyConnect; 1343; 2 N-Linked glycans (1 site). DR GlyConnect; 1344; 3 N-Linked glycans (1 site). DR GlyConnect; 1345; 1 N-Linked glycan (1 site). DR GlyConnect; 1346; 3 N-Linked glycans (1 site). DR GlyConnect; 1347; 8 N-Linked glycans (1 site). DR GlyConnect; 1348; 2 N-Linked glycans (1 site). DR GlyConnect; 1349; 2 N-Linked glycans (1 site). DR GlyConnect; 1350; 8 N-Linked glycans (1 site). DR GlyConnect; 1351; 2 N-Linked glycans (1 site). DR GlyCosmos; P01889; 2 sites, 2 glycans. DR GlyGen; P01889; 3 sites, 1 N-linked glycan (1 site), 2 O-linked glycans (2 sites). DR iPTMnet; P01889; -. DR PhosphoSitePlus; P01889; -. DR SwissPalm; P01889; -. DR BioMuta; HLA-B; -. DR DMDM; 122160; -. DR EPD; P01889; -. DR jPOST; P01889; -. DR MassIVE; P01889; -. DR MaxQB; P01889; -. DR PaxDb; 9606-ENSP00000399168; -. DR PeptideAtlas; P01889; -. DR ProteomicsDB; 51504; -. DR ProteomicsDB; 51628; -. DR ProteomicsDB; 52598; -. DR ProteomicsDB; 53565; -. DR ProteomicsDB; 53566; -. DR ProteomicsDB; 53567; -. DR ProteomicsDB; 54677; -. DR ProteomicsDB; 54678; -. DR ProteomicsDB; 54679; -. DR ProteomicsDB; 54680; -. DR ProteomicsDB; 54681; -. DR ProteomicsDB; 54682; -. DR ProteomicsDB; 54683; -. DR ProteomicsDB; 54684; -. DR ProteomicsDB; 54685; -. DR ProteomicsDB; 54686; -. DR ProteomicsDB; 54687; -. DR ProteomicsDB; 54688; -. DR ProteomicsDB; 54689; -. DR ProteomicsDB; 54690; -. DR ProteomicsDB; 54691; -. DR ProteomicsDB; 54692; -. DR ProteomicsDB; 54693; -. DR ProteomicsDB; 54694; -. DR ProteomicsDB; 54695; -. DR ProteomicsDB; 54696; -. DR ProteomicsDB; 54697; -. DR ProteomicsDB; 54732; -. DR ProteomicsDB; 58284; -. DR ProteomicsDB; 61272; -. DR ProteomicsDB; 61273; -. DR ProteomicsDB; 61276; -. DR ProteomicsDB; 61584; -. DR ProteomicsDB; 61586; -. DR ProteomicsDB; 75730; -. DR Pumba; P01889; -. DR Antibodypedia; 26900; 808 antibodies from 35 providers. DR CPTC; P01889; 1 antibody. DR DNASU; 3106; -. DR Ensembl; ENST00000412585.7; ENSP00000399168.2; ENSG00000234745.14. DR Ensembl; ENST00000696559.1; ENSP00000512717.1; ENSG00000234745.14. DR Ensembl; ENST00000696560.1; ENSP00000512718.1; ENSG00000234745.14. DR Ensembl; ENST00000696561.1; ENSP00000512719.1; ENSG00000234745.14. DR Ensembl; ENST00000696562.1; ENSP00000512720.1; ENSG00000234745.14. DR GeneID; 3106; -. DR KEGG; hsa:3106; -. DR MANE-Select; ENST00000412585.7; ENSP00000399168.2; NM_005514.8; NP_005505.2. DR UCSC; uc011fcq.2; human. DR UCSC; uc011hpp.3; human. DR UCSC; uc011jij.3; human. DR AGR; HGNC:4932; -. DR CTD; 3106; -. DR DisGeNET; 3106; -. DR GeneCards; HLA-B; -. DR HGNC; HGNC:4932; HLA-B. DR HPA; ENSG00000234745; Tissue enhanced (lymphoid). DR MalaCards; HLA-B; -. DR MIM; 106300; phenotype. DR MIM; 608579; phenotype. DR neXtProt; NX_P01889; -. DR OpenTargets; ENSG00000234745; -. DR Orphanet; 117; Behcet disease. DR Orphanet; 397; Giant cell arteritis. DR Orphanet; 825; NON RARE IN EUROPE: Ankylosing spondylitis. DR Orphanet; 275798; Pulmonary arterial hypertension associated with connective tissue disease. DR Orphanet; 29207; Reactive arthritis. DR Orphanet; 36426; Stevens-Johnson syndrome. DR Orphanet; 3287; Takayasu arteritis. DR PharmGKB; PA35056; -. DR VEuPathDB; HostDB:ENSG00000234745; -. DR eggNOG; ENOG502RQEK; Eukaryota. DR GeneTree; ENSGT00980000198488; -. DR HOGENOM; CLU_047501_1_1_1; -. DR InParanoid; P01889; -. DR OMA; KNERWIA; -. DR OrthoDB; 3840485at2759; -. DR PhylomeDB; P01889; -. DR TreeFam; TF336617; -. DR PathwayCommons; P01889; -. DR Reactome; R-HSA-1236974; ER-Phagosome pathway. DR Reactome; R-HSA-1236977; Endosomal/Vacuolar pathway. DR Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell. DR Reactome; R-HSA-2172127; DAP12 interactions. DR Reactome; R-HSA-6798695; Neutrophil degranulation. DR Reactome; R-HSA-877300; Interferon gamma signaling. DR Reactome; R-HSA-909733; Interferon alpha/beta signaling. DR Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses. DR Reactome; R-HSA-983170; Antigen Presentation: Folding, assembly and peptide loading of class I MHC. DR SignaLink; P01889; -. DR SIGNOR; P01889; -. DR BioGRID-ORCS; 3106; 25 hits in 1092 CRISPR screens. DR ChiTaRS; HLA-B; human. DR GeneWiki; HLA-B; -. DR GenomeRNAi; 3106; -. DR Pharos; P01889; Tbio. DR PRO; PR:P01889; -. DR Proteomes; UP000005640; Chromosome 6. DR Bgee; ENSG00000234745; Expressed in blood and 101 other cell types or tissues. DR ExpressionAtlas; P01889; baseline and differential. DR GO; GO:0009986; C:cell surface; IDA:UniProtKB. DR GO; GO:0031901; C:early endosome membrane; TAS:Reactome. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome. DR GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; IBA:GO_Central. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0098553; C:lumenal side of endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0042612; C:MHC class I protein complex; IDA:UniProtKB. DR GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0055038; C:recycling endosome membrane; TAS:Reactome. DR GO; GO:0030667; C:secretory granule membrane; TAS:Reactome. DR GO; GO:0042605; F:peptide antigen binding; IDA:UniProtKB. DR GO; GO:0051087; F:protein-folding chaperone binding; IPI:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB. DR GO; GO:0046977; F:TAP binding; IDA:UniProtKB. DR GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW. DR GO; GO:0002486; P:antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent; IDA:UniProtKB. DR GO; GO:0002476; P:antigen processing and presentation of endogenous peptide antigen via MHC class Ib; IBA:GO_Central. DR GO; GO:0006952; P:defense response; TAS:UniProtKB. DR GO; GO:0016045; P:detection of bacterium; IMP:UniProtKB. DR GO; GO:0006955; P:immune response; IMP:UniProtKB. DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW. DR GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; IDA:UniProtKB. DR GO; GO:0042270; P:protection from natural killer cell mediated cytotoxicity; IDA:UniProtKB. DR GO; GO:2001198; P:regulation of dendritic cell differentiation; IMP:BHF-UCL. DR GO; GO:0032655; P:regulation of interleukin-12 production; IMP:BHF-UCL. DR GO; GO:0032675; P:regulation of interleukin-6 production; IMP:BHF-UCL. DR GO; GO:0002667; P:regulation of T cell anergy; IMP:BHF-UCL. DR CDD; cd21026; IgC1_MHC_Ia_HLA-B; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR Gene3D; 3.30.500.10; MHC class I-like antigen recognition-like; 1. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003006; Ig/MHC_CS. DR InterPro; IPR003597; Ig_C1-set. DR InterPro; IPR011161; MHC_I-like_Ag-recog. DR InterPro; IPR037055; MHC_I-like_Ag-recog_sf. DR InterPro; IPR011162; MHC_I/II-like_Ag-recog. DR InterPro; IPR001039; MHC_I_a_a1/a2. DR InterPro; IPR010579; MHC_I_a_C. DR PANTHER; PTHR16675:SF270; HLA CLASS I HISTOCOMPATIBILITY ANTIGEN, B ALPHA CHAIN; 1. DR PANTHER; PTHR16675; MHC CLASS I-RELATED; 1. DR Pfam; PF07654; C1-set; 1. DR Pfam; PF00129; MHC_I; 1. DR Pfam; PF06623; MHC_I_C; 1. DR PRINTS; PR01638; MHCCLASSI. DR SMART; SM00407; IGc1; 1. DR SUPFAM; SSF48726; Immunoglobulin; 1. DR SUPFAM; SSF54452; MHC antigen-recognition domain; 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS00290; IG_MHC; 1. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; Cell membrane; Direct protein sequencing; KW Disulfide bond; Endoplasmic reticulum; Glycoprotein; KW Host-virus interaction; Immunity; Innate immunity; Membrane; MHC I; KW Phosphoprotein; Reference proteome; Signal; Transmembrane; KW Transmembrane helix. FT SIGNAL 1..24 FT /evidence="ECO:0000269|PubMed:518865" FT CHAIN 25..362 FT /note="HLA class I histocompatibility antigen, B alpha FT chain" FT /id="PRO_0000018833" FT TOPO_DOM 25..309 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 310..333 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 334..362 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 209..295 FT /note="Ig-like C1-type" FT REGION 3..11 FT /note="VL9 epitope" FT /evidence="ECO:0000269|PubMed:37264229" FT REGION 25..114 FT /note="Alpha-1" FT /evidence="ECO:0000255" FT REGION 115..206 FT /note="Alpha-2" FT /evidence="ECO:0000255" FT REGION 207..298 FT /note="Alpha-3" FT /evidence="ECO:0000255" FT REGION 299..309 FT /note="Connecting peptide" FT /evidence="ECO:0000255" FT REGION 337..362 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 101..107 FT /note="Bw6 motif" FT /evidence="ECO:0000269|PubMed:25480565" FT COMPBIAS 339..362 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 87 FT /ligand="a peptide antigen" FT /ligand_id="ChEBI:CHEBI:166823" FT /ligand_note="pathogen-derived peptide antigen" FT /evidence="ECO:0000269|PubMed:25808313" FT BINDING 108 FT /ligand="a peptide antigen" FT /ligand_id="ChEBI:CHEBI:166823" FT /ligand_note="pathogen-derived peptide antigen" FT /evidence="ECO:0000269|PubMed:25808313" FT BINDING 167 FT /ligand="a peptide antigen" FT /ligand_id="ChEBI:CHEBI:166823" FT /ligand_note="pathogen-derived peptide antigen" FT /evidence="ECO:0000269|PubMed:25808313" FT BINDING 170 FT /ligand="a peptide antigen" FT /ligand_id="ChEBI:CHEBI:166823" FT /ligand_note="pathogen-derived peptide antigen" FT /evidence="ECO:0000269|PubMed:25808313" FT BINDING 176 FT /ligand="a peptide antigen" FT /ligand_id="ChEBI:CHEBI:166823" FT /ligand_note="pathogen-derived peptide antigen" FT /evidence="ECO:0000269|PubMed:25808313" FT BINDING 183 FT /ligand="a peptide antigen" FT /ligand_id="ChEBI:CHEBI:166823" FT /ligand_note="pathogen-derived peptide antigen" FT /evidence="ECO:0000269|PubMed:25808313" FT BINDING 195 FT /ligand="a peptide antigen" FT /ligand_id="ChEBI:CHEBI:166823" FT /ligand_note="pathogen-derived peptide antigen" FT /evidence="ECO:0000269|PubMed:25808313" FT CARBOHYD 110 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19159218" FT DISULFID 125..188 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:17057332, ECO:0000269|PubMed:25808313, FT ECO:0000269|PubMed:29531227" FT DISULFID 227..283 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:17057332, ECO:0000269|PubMed:25808313, FT ECO:0000269|PubMed:29531227" FT VARIANT 2 FT /note="L -> R (in allele B*13:02, allele B*15:01, allele FT B*18:01, allele B*27:01, allele B*27:05, allele B*35:01, FT allele B*37:01, allele B*40:01, allele B*40:02, allele FT B*41:01, allele B*44:02, allele B*45:01, allele B*46:01, FT allele B*47:01, allele B*49:01, allele B*50:01, allele FT B*51:01, allele B*52:01, allele B*53:01, allele B*54:01, FT allele B*55:01, allele B*56:01, allele B*57:01, allele FT B*58:01, allele B*59:01, allele B*78:01 and allele B*82:01; FT dbSNP:rs9266206)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584, FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8773315, FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46, FT ECO:0000269|Ref.47" FT /id="VAR_082483" FT VARIANT 4 FT /note="M -> T (in allele B*13:02, allele B*15:01, allele FT B*18:01, allele B*27:01, allele B*27:05, allele B*35:01, FT allele B*37:01, allele B*40:01, allele B*40:02, allele FT B*41:01, allele B*44:02, allele B*45:01, allele B*46:01, FT allele B*47:01, allele B*49:01, allele B*50:01, allele FT B*51:01, allele B*52:01, allele B*53:01, allele B*54:01, FT allele B*55:01, allele B*56:01, allele B*57:01, allele FT B*58:01, allele B*59:01, allele B*78:01 and allele B*82:01; FT dbSNP:rs1050458)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584, FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8773315, FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46, FT ECO:0000269|Ref.47" FT /id="VAR_082484" FT VARIANT 9 FT /note="V -> L (in allele B*13:02, allele B*18:01, allele FT B*27:01, allele B*27:05, allele B*37:01, allele B*40:02, FT allele B*44:02, allele B*47:01, allele B*54:01, allele FT B*55:01, allele B*56:01, allele B*59:01 and allele B*82:01; FT dbSNP:rs1050462)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1481202, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:8362411, ECO:0000269|Ref.37, FT ECO:0000269|Ref.38, ECO:0000269|Ref.42, ECO:0000269|Ref.44, FT ECO:0000269|Ref.46, ECO:0000269|Ref.47" FT /id="VAR_082485" FT VARIANT 14 FT /note="S -> W (in allele B*13:02, allele B*18:01, allele FT B*27:01, allele B*27:05, allele B*35:01, allele B*37:01, FT allele B*40:02, allele B*44:02, allele B*47:01, allele FT B*51:01, allele B*52:01, allele B*53:01, allele B*54:01, FT allele B*55:01, allele B*56:01, allele B*57:01, allele FT B*58:01, allele B*59:01, allele B*78:01, allele B*81:01 and FT allele B*82:01; dbSNP:rs1131156)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202, FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1699887, FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8740766, FT ECO:0000269|PubMed:8847228, ECO:0000269|PubMed:8851728, FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46, FT ECO:0000269|Ref.47" FT /id="VAR_082486" FT VARIANT 15 FT /note="A -> G (in allele B*13:02, allele B*15:01, allele FT B*18:01, allele B*27:01, allele B*27:05, allele B*35:01, FT allele B*37:01, allele B*40:02, allele B*44:02, allele FT B*46:01, allele B*47:01, allele B*51:01, allele B*52:01, FT allele B*53:01, allele B*54:01, allele B*55:01, allele FT B*56:01, allele B*57:01, allele B*58:01, allele B*59:01, FT allele B*78:01, allele B*81:01 and allele B*82:01; FT dbSNP:rs1131159)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202, FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1699887, FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:8362411, FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8740766, FT ECO:0000269|PubMed:8773315, ECO:0000269|PubMed:8847228, FT ECO:0000269|PubMed:8851728, ECO:0000269|Ref.37, FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.42, FT ECO:0000269|Ref.44, ECO:0000269|Ref.46, ECO:0000269|Ref.47" FT /id="VAR_082487" FT VARIANT 17 FT /note="L -> V (in allele B*13:02, allele B*18:01, allele FT B*27:01, allele B*27:05, allele B*35:01, allele B*37:01, FT allele B*40:02, allele B*44:02, allele B*47:01, allele FT B*51:01, allele B*52:01, allele B*53:01, allele B*57:01, FT allele B*58:01, allele B*78:01 and allele B*81:01; FT dbSNP:rs1131165)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202, FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1699887, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131, FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:3011411, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:8847228, FT ECO:0000269|PubMed:8851728, ECO:0000269|Ref.37, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46" FT /id="VAR_082488" FT VARIANT 33 FT /note="Y -> D (in allele B*08:01; associated with increased FT risk for rheumatoid arthritis; dbSNP:rs2596492)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:22286218, ECO:0000269|PubMed:2715640, FT ECO:0000269|Ref.48" FT /id="VAR_082489" FT VARIANT 33 FT /note="Y -> H (in allele B*18:01, allele B*27:01, allele FT B*27:05, allele B*37:01, allele B*40:01, allele B*40:02, FT allele B*41:01, allele B*45:01, allele B*49:01, allele FT B*50:01 and allele B*73:01; dbSNP:rs2596492)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202, FT ECO:0000269|PubMed:21868630, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3489755, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7517915, FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:8547229, FT ECO:0000269|Ref.37, ECO:0000269|Ref.44, ECO:0000269|Ref.46" FT /id="VAR_082490" FT VARIANT 35 FT /note="S -> A (in allele B*08:01, allele B*13:02, allele FT B*15:01, allele B*35:01, allele B*40:01, allele B*41:01, FT allele B*44:02, allele B*45:01, allele B*46:01, allele FT B*47:01, allele B*49:01, allele B*50:01, allele B*51:01, FT allele B*52:01, allele B*53:01, allele B*54:01, allele FT B*55:01, allele B*56:01, allele B*57:01, allele B*58:01, FT allele B*59:01, allele B*78:01 and allele B*82:01; FT dbSNP:rs1131170)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7517584, FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8773315, FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.47, FT ECO:0000269|Ref.48" FT /id="VAR_082491" FT VARIANT 36 FT /note="V -> M (in allele B*08:01, allele B*13:02, allele FT B*15:01, allele B*35:01, allele B*40:01, allele B*41:01, FT allele B*44:02, allele B*45:01, allele B*46:01, allele FT B*47:01, allele B*49:01, allele B*50:01, allele B*51:01, FT allele B*52:01, allele B*53:01, allele B*54:01, allele FT B*55:01, allele B*56:01, allele B*57:01, allele B*58:01, FT allele B*59:01, allele B*78:01 and allele B*82:01; FT dbSNP:rs1050486)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7517584, FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8773315, FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.47, FT ECO:0000269|Ref.48" FT /id="VAR_082492" FT VARIANT 48 FT /note="S -> A (in allele B*15:01, allele B*35:01, allele FT B*46:01, allele B*51:01, allele B*52:01, allele B*53:01, FT allele B*54:01, allele B*55:01, allele B*56:01, allele FT B*57:01, allele B*58:01, allele B*59:01 and allele B*78:01; FT dbSNP:rs713031)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1699887, FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:8362411, FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8773315, FT ECO:0000269|Ref.38, ECO:0000269|Ref.44, ECO:0000269|Ref.47" FT /id="VAR_082493" FT VARIANT 48 FT /note="S -> T (in allele B*13:02, allele B*27:01, allele FT B*27:05, allele B*40:01, allele B*40:02, allele B*41:01, FT allele B*44:02, allele B*45:01, allele B*47:01, allele FT B*49:01, allele B*50:01 and allele B*73:01; FT dbSNP:rs713031)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202, FT ECO:0000269|PubMed:21868630, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3011411, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7517915, FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:8547229, ECO:0000269|Ref.37, FT ECO:0000269|Ref.42, ECO:0000269|Ref.46" FT /id="VAR_082494" FT VARIANT 54 FT /note="D -> G (in allele B*18:01; dbSNP:rs9266183)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:2715640" FT /id="VAR_082495" FT VARIANT 56 FT /note="Q -> L (in allele B*27:01, allele B*27:05, allele FT B*40:01, allele B*40:02, allele B*41:01, allele B*44:02, FT allele B*45:01, allele B*47:01, allele B*49:01 and allele FT B*50:01; dbSNP:rs1050518)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202, FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584, FT ECO:0000269|Ref.37, ECO:0000269|Ref.42, ECO:0000269|Ref.46" FT /id="VAR_082496" FT VARIANT 65 FT /note="A -> T (in allele B*13:02, allele B*40:01, allele FT B*40:02, allele B*41:01, allele B*44:02, allele B*45:01, FT allele B*47:01, allele B*49:01 and allele B*50:01; FT dbSNP:rs1050529)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202, FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7517584, FT ECO:0000269|PubMed:7558929, ECO:0000269|Ref.37, FT ECO:0000269|Ref.42" FT /id="VAR_082497" FT VARIANT 69 FT /note="E -> G (in allele B*54:01; dbSNP:rs41562914)" FT /evidence="ECO:0000269|PubMed:1737933" FT /id="VAR_082498" FT VARIANT 69 FT /note="E -> K (in allele B*40:01, allele B*40:02, allele FT B*41:01, allele B*44:02, allele B*45:01, allele B*47:01, FT allele B*49:01 and allele B*50:01; dbSNP:rs9266178)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202, FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7517584, FT ECO:0000269|Ref.37, ECO:0000269|Ref.42" FT /id="VAR_082499" FT VARIANT 69 FT /note="E -> M (in allele B*13:02, allele B*15:01, allele FT B*46:01 and allele B*57:01; requires 2 nucleotide FT substitutions)" FT /evidence="ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8773315" FT /id="VAR_082500" FT VARIANT 69 FT /note="E -> T (in allele B*18:01, allele B*35:01, allele FT B*37:01, allele B*51:01, allele B*52:01, allele B*53:01, FT allele B*58:01 and allele B*78:01; requires 2 nucleotide FT substitutions)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1699887, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|Ref.37, ECO:0000269|Ref.44" FT /id="VAR_082501" FT VARIANT 70 FT /note="E -> A (in allele B*13:02, allele B*15:01, allele FT B*46:01 and allele B*57:01; dbSNP:rs1050538)" FT /evidence="ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8773315" FT /id="VAR_082502" FT VARIANT 76 FT /note="I -> V (in allele B*54:01; dbSNP:rs145974360)" FT /evidence="ECO:0000269|PubMed:1737933" FT /id="VAR_082503" FT VARIANT 86 FT /note="R -> G (in allele B*57:01 and allele B*58:01; FT dbSNP:rs141484466)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2995352" FT /id="VAR_082504" FT VARIANT 87 FT /note="N -> E (in allele B*13:02, allele B*15:01, allele FT B*27:01, allele B*27:05, allele B*37:01, allele B*39:02, FT allele B*40:01, allele B*40:02, allele B*41:01, allele FT B*44:02, allele B*45:01, allele B*46:01, allele B*47:01, FT allele B*48:01, allele B*49:01, allele B*50:01, allele FT B*52:01, allele B*57:01 and allele B*58:01; requires 2 FT nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1317015, FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584, FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8420828, FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8773315, FT ECO:0000269|Ref.37, ECO:0000269|Ref.42, ECO:0000269|Ref.44, FT ECO:0000269|Ref.46" FT /id="VAR_082505" FT VARIANT 89 FT /note="Q -> R (in allele B*57:01 and allele B*58:01; FT dbSNP:rs1131201)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2995352" FT /id="VAR_082506" FT VARIANT 90 FT /note="I -> K (in allele B*46:01)" FT /evidence="ECO:0000269|PubMed:2715640" FT /id="VAR_082507" FT VARIANT 90 FT /note="I -> N (in allele B*57:01 and allele B*58:01; FT dbSNP:rs1131202)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2995352" FT /id="VAR_082508" FT VARIANT 91 FT /note="Y -> C (in allele B*14:01, allele B*27:01, allele FT B*27:05, allele B*38:01 and allele B*73:01; FT dbSNP:rs1071816)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3011411, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517915, FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7725307, FT ECO:0000269|PubMed:8547229, ECO:0000269|Ref.41, FT ECO:0000269|Ref.46" FT /id="VAR_082509" FT VARIANT 91 FT /note="Y -> F (in allele B*08:01, allele B*35:01, allele FT B*51:01, allele B*53:01, allele B*59:01 and allele B*78:01; FT dbSNP:rs1071816)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:8362411, FT ECO:0000269|Ref.38, ECO:0000269|Ref.44, ECO:0000269|Ref.48" FT /id="VAR_082510" FT VARIANT 91 FT /note="Y -> M (in allele B*57:01 and allele B*58:01; FT requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2995352" FT /id="VAR_082511" FT VARIANT 91 FT /note="Y -> S (in allele B*13:02, allele B*15:01, allele FT B*18:01, allele B*37:01, allele B*39:02, allele B*40:01, FT allele B*40:02, allele B*41:01, allele B*44:02, allele FT B*45:01, allele B*47:01, allele B*48:01, allele B*49:01, FT allele B*50:01 and allele B*52:01; dbSNP:rs1071816)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:1362296, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307, FT ECO:0000269|PubMed:8420828, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44" FT /id="VAR_082512" FT VARIANT 93 FT /note="A -> R (in allele B*46:01; requires 2 nucleotide FT substitutions)" FT /evidence="ECO:0000269|PubMed:2715640" FT /id="VAR_082513" FT VARIANT 93 FT /note="A -> T (in allele B*08:01, allele B*13:02, allele FT B*14:01, allele B*15:01, allele B*18:01, allele B*35:01, FT allele B*37:01, allele B*38:01, allele B*39:02, allele FT B*40:01, allele B*40:02, allele B*41:01, allele B*44:02, FT allele B*45:01, allele B*47:01, allele B*48:01, allele FT B*49:01, allele B*50:01, allele B*51:01, allele B*52:01, FT allele B*53:01, allele B*59:01 and allele B*78:01; FT dbSNP:rs1131204)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:1362296, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828, FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8773315, FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.41, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.48" FT /id="VAR_082514" FT VARIANT 94 FT /note="Q -> K (in allele B*27:01, allele B*27:05 and allele FT B*73:01; dbSNP:rs1071817)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3489755, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:8547229, ECO:0000269|Ref.46" FT /id="VAR_082515" FT VARIANT 94 FT /note="Q -> N (in allele B*08:01, allele B*13:02, allele FT B*14:01, allele B*15:01, allele B*18:01, allele B*35:01, FT allele B*37:01, allele B*38:01, allele B*39:02, allele FT B*40:01, allele B*40:02, allele B*41:01, allele B*44:02, FT allele B*45:01, allele B*47:01, allele B*48:01, allele FT B*49:01, allele B*50:01, allele B*51:01, allele B*52:01, FT allele B*53:01, allele B*59:01 and allele B*78:01; requires FT 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:1362296, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828, FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8773315, FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.41, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.48" FT /id="VAR_082516" FT VARIANT 94 FT /note="Q -> S (in allele B*57:01 and allele B*58:01; FT requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2995352" FT /id="VAR_082517" FT VARIANT 95 FT /note="A -> T (in allele B*08:01, allele B*13:02, allele FT B*14:01, allele B*15:01, allele B*18:01, allele B*35:01, FT allele B*37:01, allele B*38:01, allele B*39:02, allele FT B*40:01, allele B*40:02, allele B*41:01, allele B*44:02, FT allele B*45:01, allele B*47:01, allele B*48:01, allele FT B*49:01, allele B*50:01, allele B*51:01, allele B*52:01, FT allele B*53:01, allele B*59:01 and allele B*78:01; FT dbSNP:rs1131213)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:1362296, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828, FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8773315, FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.41, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.48" FT /id="VAR_082518" FT VARIANT 98 FT /note="D -> Y (in allele B*13:02, allele B*15:01, allele FT B*18:01, allele B*27:01, allele B*35:01, allele B*37:01, FT allele B*38:01, allele B*40:01, allele B*40:02, allele FT B*41:01, allele B*44:02, allele B*45:01, allele B*47:01, FT allele B*48:01, allele B*49:01, allele B*50:01, allele FT B*51:01, allele B*52:01, allele B*53:01, allele B*57:01, FT allele B*58:01 and allele B*59:01; dbSNP:rs1131215)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1317015, FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2714852, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131, FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37, FT ECO:0000269|Ref.38, ECO:0000269|Ref.41, ECO:0000269|Ref.42, FT ECO:0000269|Ref.44, ECO:0000269|Ref.46" FT /id="VAR_082519" FT VARIANT 100 FT /note="E -> V (in allele B*46:01 and allele B*73:01; FT dbSNP:rs41553715)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:7517915, FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:8547229" FT /id="VAR_082520" FT VARIANT 101 FT /note="S -> D (in allele B*27:05, allele B*37:01 and allele FT B*47:01; requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:3011411, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755, FT ECO:0000269|Ref.37, ECO:0000269|Ref.44" FT /id="VAR_082521" FT VARIANT 101 FT /note="S -> G (in allele B*73:01; dbSNP:rs1131217)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:8547229" FT /id="VAR_082522" FT VARIANT 101 FT /note="S -> N (in allele B*13:02, allele B*27:01, allele FT B*38:01, allele B*44:02, allele B*49:01, allele B*51:01, FT allele B*52:01, allele B*53:01, allele B*57:01, allele FT B*58:01 and allele B*59:01; dbSNP:rs1050388)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1699887, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411, FT ECO:0000269|Ref.38, ECO:0000269|Ref.41, ECO:0000269|Ref.46" FT /id="VAR_082523" FT VARIANT 104 FT /note="N -> I (in allele B*38:01, allele B*49:01, allele FT B*51:01, allele B*52:01, allele B*53:01, allele B*57:01 and FT allele B*59:01; part of Bw4 motif involved in the FT recognition of KIR3DL1; dbSNP:rs1131223)" FT /evidence="ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:22020283, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:25480565, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:7725307, FT ECO:0000269|Ref.41" FT /id="VAR_082524" FT VARIANT 104 FT /note="N -> T (in allele B*13:02, allele B*27:01, allele FT B*27:05, allele B*37:01, allele B*44:02 and allele B*47:01; FT dbSNP:rs1131223)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7558929, FT ECO:0000269|Ref.37, ECO:0000269|Ref.42, ECO:0000269|Ref.44, FT ECO:0000269|Ref.46" FT /id="VAR_082525" FT VARIANT 105 FT /note="L -> A (in allele B*13:02, allele B*27:01, allele FT B*38:01, allele B*44:02, allele B*49:01, allele B*51:01, FT allele B*52:01, allele B*53:01, allele B*57:01, allele FT B*58:01 and allele B*59:01; requires 2 nucleotide FT substitutions)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1699887, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411, FT ECO:0000269|Ref.38, ECO:0000269|Ref.41, ECO:0000269|Ref.42, FT ECO:0000269|Ref.46" FT /id="VAR_082526" FT VARIANT 106 FT /note="R -> L (in allele B*13:02, allele B*27:01, allele FT B*27:05, allele B*37:01, allele B*38:01, allele B*44:02, FT allele B*49:01, allele B*51:01, allele B*52:01, allele FT B*53:01, allele B*57:01, allele B*58:01 and allele B*59:01; FT dbSNP:rs3180379)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1699887, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411, FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.41, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46" FT /id="VAR_082527" FT VARIANT 107 FT /note="G -> R (in allele B*13:02, allele B*27:01, allele FT B*27:05, allele B*37:01, allele B*38:01, allele B*44:02, FT allele B*47:01, allele B*49:01, allele B*51:01, allele FT B*52:01, allele B*53:01, allele B*57:01, allele B*58:01 and FT allele B*59:01; part of Bw4 motif involved in the FT recognition of KIR3DL1; dbSNP:rs3180380)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:22020283, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:25480565, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:3011411, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307, FT ECO:0000269|PubMed:8362411, ECO:0000269|Ref.37, FT ECO:0000269|Ref.38, ECO:0000269|Ref.41, ECO:0000269|Ref.42, FT ECO:0000269|Ref.44, ECO:0000269|Ref.46" FT /id="VAR_082528" FT VARIANT 114 FT /note="A -> D (in allele B*73:01; dbSNP:rs41559314)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:8547229" FT /id="VAR_082529" FT VARIANT 118 FT /note="T -> I (in allele B*35:01, allele B*44:02, allele FT B*53:01, allele B*57:01 and allele B*58:01; FT dbSNP:rs12721827)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|Ref.42" FT /id="VAR_082530" FT VARIANT 119 FT /note="L -> I (in allele B*35:01, allele B*37:01, allele FT B*44:02, allele B*53:01, allele B*57:01 and allele B*58:01; FT dbSNP:rs12721829)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131, FT ECO:0000269|PubMed:2995352, ECO:0000269|Ref.37, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44" FT /id="VAR_082531" FT VARIANT 119 FT /note="L -> W (in allele B*13:02, allele B*41:01, allele FT B*45:01, allele B*49:01, allele B*50:01, allele B*51:01, FT allele B*52:01, allele B*54:01, allele B*55:01, allele FT B*56:01, allele B*59:01, allele B*73:01 and allele FT B*78:01)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1737933, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:8362411, FT ECO:0000269|PubMed:8547229, ECO:0000269|Ref.37, FT ECO:0000269|Ref.38, ECO:0000269|Ref.44, ECO:0000269|Ref.47" FT /id="VAR_082532" FT VARIANT 121 FT /note="S -> N (in allele B*27:01 and allele B*27:05; FT dbSNP:rs1071652)" FT /evidence="ECO:0000269|PubMed:3011411, FT ECO:0000269|PubMed:3489755, ECO:0000269|Ref.46" FT /id="VAR_082533" FT VARIANT 121 FT /note="S -> R (in allele B*15:01, allele B*18:01, allele FT B*35:01, allele B*37:01, allele B*38:01, allele B*39:02, FT allele B*40:01, allele B*41:01, allele B*44:02, allele FT B*45:01, allele B*46:01, allele B*47:01, allele B*49:01, FT allele B*50:01, allele B*53:01, allele B*58:01, allele FT B*67:01 and allele B*82:01; dbSNP:rs1140412)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1699887, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131, FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8420828, FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8740766, FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37, FT ECO:0000269|Ref.40, ECO:0000269|Ref.41, ECO:0000269|Ref.42, FT ECO:0000269|Ref.44" FT /id="VAR_082534" FT VARIANT 121 FT /note="S -> T (in allele B*13:02, allele B*51:01, allele FT B*52:01, allele B*54:01, allele B*55:01, allele B*56:01, FT allele B*59:01, allele B*73:01 and allele B*78:01; FT dbSNP:rs1071652)" FT /evidence="ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1737933, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:8362411, FT ECO:0000269|PubMed:8547229, ECO:0000269|Ref.38, FT ECO:0000269|Ref.44, ECO:0000269|Ref.47" FT /id="VAR_082535" FT VARIANT 121 FT /note="S -> V (in allele B*57:01; requires 2 nucleotide FT substitutions)" FT /evidence="ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591" FT /id="VAR_082536" FT VARIANT 121 FT /note="S -> W (in allele B*14:01)" FT /evidence="ECO:0000269|PubMed:2715640" FT /id="VAR_082537" FT VARIANT 123 FT /note="Y -> F (in allele B*47:01 and allele B*82:01; FT dbSNP:rs151341218)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:8740766, FT ECO:0000269|Ref.40" FT /id="VAR_082538" FT VARIANT 123 FT /note="Y -> S (in allele B*37:01; dbSNP:rs151341218)" FT /evidence="ECO:0000269|PubMed:2320591, ECO:0000269|Ref.37, FT ECO:0000269|Ref.44" FT /id="VAR_082539" FT VARIANT 127 FT /note="V -> L (in allele B*13:02, allele B*35:01, allele FT B*45:01, allele B*49:01, allele B*50:01, allele B*53:01, FT allele B*54:01, allele B*55:01, allele B*56:01, allele FT B*58:01, allele B*59:01 and allele B*82:01; FT dbSNP:rs1131112)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1699887, FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8740766, FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40, FT ECO:0000269|Ref.47" FT /id="VAR_082540" FT VARIANT 127 FT /note="V -> M (in allele B*73:01; dbSNP:rs1131112)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:8547229" FT /id="VAR_082541" FT VARIANT 137 FT /note="H -> Y (in allele B*14:01, allele B*27:01, allele FT B*27:05, allele B*37:01, allele B*44:02, allele B*45:01, FT allele B*47:01, allele B*49:01, allele B*50:01 and allele FT B*73:01; dbSNP:rs1050379)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:21868630, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3011411, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:8547229, ECO:0000269|Ref.37, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46" FT /id="VAR_082542" FT VARIANT 138 FT /note="D -> H (in allele B*27:01, allele B*27:05 and allele FT B*47:01; dbSNP:rs709055)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|Ref.46" FT /id="VAR_082543" FT VARIANT 138 FT /note="D -> N (in allele B*08:01, allele B*13:02, allele FT B*14:01, allele B*37:01, allele B*38:01, allele B*39:02, FT allele B*40:01, allele B*40:02, allele B*41:01, allele FT B*42:01, allele B*45:01, allele B*48:01, allele B*49:01, FT allele B*50:01, allele B*51:01, allele B*52:01, allele FT B*54:01, allele B*55:01, allele B*56:01, allele B*59:01, FT allele B*67:01, allele B*73:01, allele B*78:01, allele FT B*81:01 and allele B*82:01; dbSNP:rs709055)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:1362296, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:21868630, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2714852, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7517915, FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411, FT ECO:0000269|PubMed:8420828, ECO:0000269|PubMed:8547229, FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8847228, FT ECO:0000269|PubMed:8851728, ECO:0000269|Ref.37, FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.41, FT ECO:0000269|Ref.44, ECO:0000269|Ref.47, ECO:0000269|Ref.48, FT ECO:0007744|PubMed:25944712" FT /id="VAR_082544" FT VARIANT 140 FT /note="Y -> D (in allele B*27:01, allele B*27:05, allele FT B*44:02 and allele B*47:01; dbSNP:rs9266150)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:3011411, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755, FT ECO:0000269|Ref.42, ECO:0000269|Ref.46" FT /id="VAR_082545" FT VARIANT 140 FT /note="Y -> F (in allele B*14:01, allele B*37:01, allele FT B*38:01, allele B*39:02, allele B*67:01 and allele B*73:01; FT dbSNP:rs4997052)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7517915, FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7725307, FT ECO:0000269|PubMed:8420828, ECO:0000269|PubMed:8547229, FT ECO:0000269|Ref.37, ECO:0000269|Ref.41, ECO:0000269|Ref.44" FT /id="VAR_082546" FT VARIANT 140 FT /note="Y -> L (in allele B*13:02, allele B*45:01, allele FT B*49:01, allele B*50:01, allele B*54:01, allele B*55:01, FT allele B*56:01, allele B*59:01 and allele B*82:01; requires FT 2 nucleotide substitutions; dbSNP:rs796516815)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8740766, FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40, FT ECO:0000269|Ref.47" FT /id="VAR_082547" FT VARIANT 140 FT /note="Y -> S (in allele B*15:01, allele B*18:01, allele FT B*35:01, allele B*46:01, allele B*53:01, allele B*57:01 and FT allele B*58:01; dbSNP:rs4997052)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1699887, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131, FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8773315" FT /id="VAR_082548" FT VARIANT 155 FT /note="R -> S (in allele B*13:02, allele B*14:01, allele FT B*15:01, allele B*18:01, allele B*27:01, allele B*27:05, FT allele B*35:01, allele B*37:01, allele B*38:01, allele FT B*39:02, allele B*44:02, allele B*45:01, allele B*46:01, FT allele B*47:01, allele B*49:01, allele B*50:01, allele FT B*51:01, allele B*52:01, allele B*53:01, allele B*54:01, FT allele B*55:01, allele B*56:01, allele B*57:01, allele FT B*58:01, allele B*59:01, allele B*67:01, allele B*78:01 and FT allele B*82:01; dbSNP:rs1050654)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131, FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:3011411, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:3489755, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828, FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8740766, FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37, FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.41, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46, FT ECO:0000269|Ref.47, ECO:0007744|PubMed:25944712" FT /id="VAR_082549" FT VARIANT 167 FT /note="T -> S (in allele B*40:01, allele B*48:01 and allele FT B*81:01; dbSNP:rs41541519)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:8847228, FT ECO:0000269|PubMed:8851728" FT /id="VAR_082550" FT VARIANT 169 FT /note="R -> L (in allele B*13:02; dbSNP:rs12697943)" FT /evidence="ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:3257938, ECO:0000269|PubMed:7558929" FT /id="VAR_082551" FT VARIANT 171 FT /note="W -> L (in allele B*40:01, allele B*48:01 and allele FT B*81:01; dbSNP:rs41551018)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:8847228, FT ECO:0000269|PubMed:8851728" FT /id="VAR_082552" FT VARIANT 176 FT /note="E -> V (in allele B*08:01, allele B*13:02, allele FT B*18:01, allele B*27:01, allele B*27:05, allele B*35:01, FT allele B*37:01, allele B*38:01, allele B*39:02, allele FT B*40:01, allele B*40:02, allele B*41:01, allele B*42:01, FT allele B*44:02, allele B*45:01, allele B*47:01, allele FT B*48:01, allele B*53:01, allele B*54:01, allele B*56:01, FT allele B*57:01, allele B*58:01, allele B*59:01, allele FT B*67:01, allele B*73:01, allele B*81:01 and allele B*82:01; FT dbSNP:rs151341293)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1317015, FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1699887, FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2437025, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828, FT ECO:0000269|PubMed:8547229, ECO:0000269|PubMed:8740766, FT ECO:0000269|PubMed:8847228, ECO:0000269|PubMed:8851728, FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40, FT ECO:0000269|Ref.41, ECO:0000269|Ref.42, ECO:0000269|Ref.44, FT ECO:0000269|Ref.46, ECO:0000269|Ref.48" FT /id="VAR_082553" FT VARIANT 180 FT /note="R -> D (in allele B*08:01, allele B*37:01, allele FT B*41:01, allele B*42:01, allele B*44:02, allele B*45:01 and FT allele B*82:01; requires 2 nucleotide substitutions; FT dbSNP:rs1203316963)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:8740766, FT ECO:0000269|Ref.37, ECO:0000269|Ref.40, ECO:0000269|Ref.42, FT ECO:0000269|Ref.44, ECO:0000269|Ref.48" FT /id="VAR_082554" FT VARIANT 180 FT /note="R -> L (in allele B*13:02, allele B*14:01, allele FT B*18:01, allele B*27:01, allele B*27:05, allele B*35:01, FT allele B*38:01, allele B*39:02, allele B*40:01, allele FT B*40:02, allele B*47:01, allele B*48:01, allele B*49:01, FT allele B*50:01, allele B*51:01, allele B*52:01, allele FT B*53:01, allele B*54:01, allele B*55:01, allele B*56:01, FT allele B*57:01, allele B*58:01, allele B*59:01, allele FT B*67:01, allele B*73:01, allele B*78:01 and allele B*81:01; FT dbSNP:rs697742)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1317015, FT ECO:0000269|PubMed:1362296, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1481202, FT ECO:0000269|PubMed:1691230, ECO:0000269|PubMed:1699887, FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:21868630, ECO:0000269|PubMed:2251138, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2437025, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:7558929, ECO:0000269|PubMed:7725307, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828, FT ECO:0000269|PubMed:8547229, ECO:0000269|PubMed:8847228, FT ECO:0000269|PubMed:8851728, ECO:0000269|Ref.37, FT ECO:0000269|Ref.38, ECO:0000269|Ref.41, ECO:0000269|Ref.44, FT ECO:0000269|Ref.46, ECO:0000269|Ref.47" FT /id="VAR_082555" FT VARIANT 180 FT /note="R -> W (in allele B*15:01 and allele B*46:01; FT dbSNP:rs9266144)" FT /evidence="ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8773315" FT /id="VAR_082556" FT VARIANT 182 FT /note="A -> T (in allele B*38:01, allele B*39:02 and allele FT B*67:01; dbSNP:rs1050683)" FT /evidence="ECO:0000269|PubMed:7517584, FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8420828, FT ECO:0000269|Ref.41" FT /id="VAR_082557" FT VARIANT 186 FT /note="G -> D (in allele B*82:01; dbSNP:rs41543920)" FT /evidence="ECO:0000269|PubMed:8740766, ECO:0000269|Ref.40" FT /id="VAR_082558" FT VARIANT 187 FT /note="E -> L (in allele B*15:01, allele B*35:01, allele FT B*44:02, allele B*45:01, allele B*46:01, allele B*49:01, FT allele B*50:01, allele B*51:01, allele B*52:01, allele FT B*53:01, allele B*56:01, allele B*57:01, allele B*58:01, FT allele B*78:01 and allele B*82:01; requires 2 nucleotide FT substitutions; dbSNP:rs796093434)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8773315, FT ECO:0000269|Ref.37, ECO:0000269|Ref.40, ECO:0000269|Ref.42, FT ECO:0000269|Ref.44" FT /id="VAR_082559" FT VARIANT 187 FT /note="E -> T (in allele B*08:01, allele B*14:01, allele FT B*18:01, allele B*37:01, allele B*38:01, allele B*39:02, FT allele B*41:01, allele B*42:01, allele B*54:01, allele FT B*55:01, allele B*59:01 and allele B*67:01; requires 2 FT nucleotide substitutions; dbSNP:rs796093434)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1737933, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:7517584, ECO:0000269|PubMed:7725307, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828, FT ECO:0000269|Ref.38, ECO:0000269|Ref.41, ECO:0000269|Ref.47, FT ECO:0000269|Ref.48" FT /id="VAR_082560" FT VARIANT 191 FT /note="W -> S (in allele B*44:02, allele B*45:01 and allele FT B*82:01; dbSNP:rs1050692)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:8740766, ECO:0000269|Ref.40, FT ECO:0000269|Ref.42" FT /id="VAR_082561" FT VARIANT 195 FT /note="Y -> H (in allele B*14:01, allele B*18:01, allele FT B*51:01, allele B*52:01, allele B*73:01 and allele B*78:01; FT dbSNP:rs1050696)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:7517915, FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:8547229, FT ECO:0000269|Ref.44" FT /id="VAR_082562" FT VARIANT 201 FT /note="D -> E (in allele B*13:02, allele B*14:01, allele FT B*15:01, allele B*18:01, allele B*27:01, allele B*27:05, FT allele B*35:01, allele B*37:01, allele B*38:01, allele FT B*39:02, allele B*40:02, allele B*44:02, allele B*45:01, FT allele B*46:01, allele B*47:01, allele B*49:01, allele FT B*50:01, allele B*51:01, allele B*52:01, allele B*53:01, FT allele B*54:01, allele B*55:01, allele B*56:01, allele FT B*57:01, allele B*58:01, allele B*59:01, allele B*67:01, FT allele B*73:01, allele B*78:01 and allele B*82:01; FT dbSNP:rs1131275)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411, FT ECO:0000269|PubMed:8420828, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8547229, ECO:0000269|PubMed:8740766, FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37, FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.41, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46, FT ECO:0000269|Ref.47" FT /id="VAR_082563" FT VARIANT 202 FT /note="K -> T (in allele B*08:01, allele B*13:02, allele FT B*14:01, allele B*15:01, allele B*18:01, allele B*27:01, FT allele B*27:05, allele B*35:01, allele B*37:01, allele FT B*38:01 allele B*39:02, allele B*40:02, allele B*41:01, FT allele B*42:01, allele B*44:02, allele B*45:01, allele FT B*46:01, allele B*47:01, allele B*49:01, allele B*50:01, FT allele B*51:01, allele B*52:01, allele B*53:01, allele FT B*54:01, allele B*55:01, allele B*56:01, allele B*57:01, FT allele B*58:01, allele B*59:01, allele B*67:01, allele FT B*73:01, allele B*78:01 and allele B*82:01; FT dbSNP:rs1131279)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411, FT ECO:0000269|PubMed:8420828, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8547229, ECO:0000269|PubMed:8740766, FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37, FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.41, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46, FT ECO:0000269|Ref.47, ECO:0000269|Ref.48" FT /id="VAR_082564" FT VARIANT 204 FT /note="E -> Q (in allele B*13:02, allele B*14:01, allele FT B*15:01, allele B*18:01, allele B*27:01, allele B*27:05, FT allele B*35:01, allele B*37:01, allele B*38:01, allele FT B*39:02, allele B*40:02, allele B*44:02, allele B*45:01, FT allele B*46:01, allele B*47:01, allele B*49:01, allele FT B*50:01, allele B*51:01, allele B*52:01, allele B*53:01, FT allele B*54:01, allele B*55:01, allele B*56:01, allele FT B*57:01, allele B*58:01, allele B*59:01, allele B*67:01, FT allele B*73:01, allele B*78:01 and allele B*82:01; FT dbSNP:rs1131285)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1362296, FT ECO:0000269|PubMed:1385528, ECO:0000269|PubMed:1431115, FT ECO:0000269|PubMed:1481202, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:2251138, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:3011411, ECO:0000269|PubMed:3257938, FT ECO:0000269|PubMed:3489755, ECO:0000269|PubMed:7517584, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7558929, FT ECO:0000269|PubMed:7725307, ECO:0000269|PubMed:8362411, FT ECO:0000269|PubMed:8420828, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8547229, ECO:0000269|PubMed:8740766, FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37, FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.41, FT ECO:0000269|Ref.42, ECO:0000269|Ref.44, ECO:0000269|Ref.46, FT ECO:0000269|Ref.47" FT /id="VAR_082565" FT VARIANT 218 FT /note="I -> V (in allele B*35:01, allele B*51:01, allele FT B*52:01, allele B*53:01, allele B*58:01 and allele B*78:01; FT dbSNP:rs1050341)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:21585707, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|Ref.44" FT /id="VAR_082566" FT VARIANT 223 FT /note="A -> V (in allele B*44:02; dbSNP:rs1050723)" FT /evidence="ECO:0000269|PubMed:2715640, ECO:0000269|Ref.42" FT /id="VAR_082567" FT VARIANT 263 FT /note="R -> G (in allele B*73:01; dbSNP:rs41545916)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:8547229" FT /id="VAR_082568" FT VARIANT 269 FT /note="A -> T (in allele B*48:01, allele B*81:01; FT dbSNP:rs2308488)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:1317015, ECO:0000269|PubMed:8847228, FT ECO:0000269|PubMed:8851728" FT /id="VAR_082569" FT VARIANT 277 FT /note="E -> Q (in allele B*73:01; dbSNP:rs41542113)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:8547229" FT /id="VAR_082570" FT VARIANT 291 FT /note="P -> Q (in allele B*73:01; dbSNP:rs1611623)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:8547229" FT /id="VAR_082571" FT VARIANT 292 FT /note="K -> E (in allele B*73:01; dbSNP:rs41541515)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:8547229" FT /id="VAR_082572" FT VARIANT 294 FT /note="L -> C (in allele B*73:01; requires 2 nucleotide FT substitutions)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:8547229" FT /id="VAR_082573" FT VARIANT 299 FT /note="E -> K (in allele B*73:01; dbSNP:rs2308500)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:8547229" FT /id="VAR_082574" FT VARIANT 306 FT /note="V -> I (in allele B*15:01, allele B*18:01, allele FT B*35:01, allele B*37:01, allele B*45:01, allele B*46:01, FT allele B*49:01, allele B*50:01, allele B*51:01, allele FT B*52:01, allele B*53:01, allele B*54:01, allele B*55:01, FT allele B*56:01, allele B*58:01, allele B*59:01, allele FT B*73:01, allele B*78:01 and allele B*82:01; FT dbSNP:rs1131500)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131, FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:7517915, FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8423049, FT ECO:0000269|PubMed:8547229, ECO:0000269|PubMed:8740766, FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37, FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.44, FT ECO:0000269|Ref.47" FT /id="VAR_082575" FT VARIANT 319..324 FT /note="AVVVIG -> VVTVAVV (in allele B*73:01)" FT /evidence="ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7524186, FT ECO:0000269|PubMed:8547229" FT /id="VAR_082576" FT VARIANT 329 FT /note="A -> T (in allele B*15:01, allele B*18:01, allele FT B*35:01, allele B*37:01, allele B*45:01, allele B*46:01, FT allele B*49:01, allele B*50:01, allele B*51:01, allele FT B*52:01, allele B*53:01, allele B*54:01, allele B*55:01, FT allele B*56:01, allele B*58:01, allele B*59:01, allele FT B*78:01 and allele B*82:01; dbSNP:rs1051488)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:2320591, FT ECO:0000269|PubMed:2714852, ECO:0000269|PubMed:2715640, FT ECO:0000269|PubMed:2788131, ECO:0000269|PubMed:2995352, FT ECO:0000269|PubMed:7521976, ECO:0000269|PubMed:8362411, FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8740766, FT ECO:0000269|PubMed:8773315, ECO:0000269|Ref.37, FT ECO:0000269|Ref.38, ECO:0000269|Ref.40, ECO:0000269|Ref.44, FT ECO:0000269|Ref.47" FT /id="VAR_082577" FT VARIANT 331 FT /note="M -> V (in allele B*47:01; dbSNP:rs41548215)" FT /evidence="ECO:0000269|PubMed:12622774, FT ECO:0000269|PubMed:3257938" FT /id="VAR_082578" FT VARIANT 349 FT /note="C -> S (in allele B*14:01, allele B*15:01, allele FT B*18:01, allele B*35:01, allele B*37:01, allele B*38:01, FT allele B*39:02, allele B*45:01, allele B*46:01, allele FT B*49:01, allele B*50:01, allele B*51:01, allele B*52:01, FT allele B*53:01, allele B*54:01, allele B*55:01, allele FT B*56:01, allele B*58:01, allele B*59:01, allele B*67:01, FT allele B*73:01, allele B*78:01 and allele B*82:01; FT dbSNP:rs2308655)" FT /evidence="ECO:0000269|PubMed:10395103, FT ECO:0000269|PubMed:12622774, ECO:0000269|PubMed:1385528, FT ECO:0000269|PubMed:1431115, ECO:0000269|PubMed:1691230, FT ECO:0000269|PubMed:1699887, ECO:0000269|PubMed:1737933, FT ECO:0000269|PubMed:21585707, ECO:0000269|PubMed:21868630, FT ECO:0000269|PubMed:2320591, ECO:0000269|PubMed:2714852, FT ECO:0000269|PubMed:2715640, ECO:0000269|PubMed:2788131, FT ECO:0000269|PubMed:2995352, ECO:0000269|PubMed:7517584, FT ECO:0000269|PubMed:7517915, ECO:0000269|PubMed:7521976, FT ECO:0000269|PubMed:7524186, ECO:0000269|PubMed:7725307, FT ECO:0000269|PubMed:8362411, ECO:0000269|PubMed:8420828, FT ECO:0000269|PubMed:8423049, ECO:0000269|PubMed:8547229, FT ECO:0000269|PubMed:8740766, ECO:0000269|PubMed:8773315, FT ECO:0000269|Ref.37, ECO:0000269|Ref.38, ECO:0000269|Ref.40, FT ECO:0000269|Ref.41, ECO:0000269|Ref.44, ECO:0000269|Ref.47" FT /id="VAR_082579" FT STRAND 27..36 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 41..43 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 45..52 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 55..61 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 64..66 FT /evidence="ECO:0007829|PDB:1K5N" FT TURN 67..69 FT /evidence="ECO:0007829|PDB:4QRS" FT STRAND 70..73 FT /evidence="ECO:0007829|PDB:6BJ8" FT HELIX 74..76 FT /evidence="ECO:0007829|PDB:1K5N" FT HELIX 77..79 FT /evidence="ECO:0007829|PDB:5WMR" FT HELIX 81..108 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 113..115 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 118..127 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 129..131 FT /evidence="ECO:0007829|PDB:5T70" FT STRAND 133..142 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 145..150 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 157..161 FT /evidence="ECO:0007829|PDB:1K5N" FT HELIX 162..173 FT /evidence="ECO:0007829|PDB:1K5N" FT HELIX 176..185 FT /evidence="ECO:0007829|PDB:1K5N" FT HELIX 187..198 FT /evidence="ECO:0007829|PDB:1K5N" FT TURN 199..204 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 210..219 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 222..235 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 238..243 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 246..248 FT /evidence="ECO:0007829|PDB:4U1S" FT HELIX 249..251 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 252..254 FT /evidence="ECO:0007829|PDB:4U1M" FT STRAND 261..263 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 265..274 FT /evidence="ECO:0007829|PDB:1K5N" FT TURN 275..277 FT /evidence="ECO:0007829|PDB:4U1L" FT HELIX 278..280 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 281..286 FT /evidence="ECO:0007829|PDB:1K5N" FT STRAND 290..292 FT /evidence="ECO:0007829|PDB:3CZF" FT STRAND 294..296 FT /evidence="ECO:0007829|PDB:1K5N" SQ SEQUENCE 362 AA; 40460 MW; 5E5A7BDE031403D6 CRC64; MLVMAPRTVL LLLSAALALT ETWAGSHSMR YFYTSVSRPG RGEPRFISVG YVDDTQFVRF DSDAASPREE PRAPWIEQEG PEYWDRNTQI YKAQAQTDRE SLRNLRGYYN QSEAGSHTLQ SMYGCDVGPD GRLLRGHDQY AYDGKDYIAL NEDLRSWTAA DTAAQITQRK WEAAREAEQR RAYLEGECVE WLRRYLENGK DKLERADPPK THVTHHPISD HEATLRCWAL GFYPAEITLT WQRDGEDQTQ DTELVETRPA GDRTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEP SSQSTVPIVG IVAGLAVLAV VVIGAVVAAV MCRRKSSGGK GGSYSQAACS DSAQGSDVSL TA //